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Abstract 
 
Aims: 
Radiotherapy quality assurance (RTQA) is now a requirement of radiotherapy trials 
since poor target volume and organ at risk (OAR) contouring has been shown to 
impact on patient outcomes within the context of clinical trials. The first hypothesis 
for this research is that statistically significant inter-observer variation exists 
amongst clinical oncologists’ target volume and OAR contours within the context of 
the pre-trial quality assurance (QA) benchmark cases for four different UK 
radiotherapy trials. The second hypothesis is directed towards confirming that 
RTQA feedback during the pre-trial benchmark period does influence contouring for 
head and neck cancers. 
 
Materials/Methods: 
Four radiotherapy trials (ART-DECO, COSTAR, IDEAL and i-START trials) that require 
all prospective investigators to submit pre-accrual benchmark cases were selected.  
All benchmark cases until November 2012 were collected in DICOM format. The 
investigator contours were grouped into either target contours (TARGET) i.e. CTV1, 
parallel OARs (OAR-P) i.e. parotid glands, lungs and heart or serial OARs (OAR-S) i.e. 
brainstem, spinal cord and oesophagus. These were then analysed using a tumour 
management group (TMG) consensus contour to determine whether statistically 
significant differences existed between them. The local conformity index (L-CI) for 
each structure was also calculated for analysis.  
 
Results: 
Analysis of the pre-trial benchmark cases revealed statistically significant 
differences (p=<0.05) between clinical oncologists’ target volume, serial and parallel 
OAR contours. Analysis of the resubmitted head and neck pre-trial benchmark cases 
also revealed statistically significant differences between first and subsequent 
submission contours. 
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Conclusions: 
This research revealed that a statistically significant difference does exist in clinical 
oncologists’ target volume and OAR contours within the pre-trial QA benchmark 
cases for both lung and head and neck cancers. It was also revealed that RTQA 
feedback during the pre-trial benchmark period had a positive and statistically 
significant impact on head and neck clinician contouring. 
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Chapter 1: Introduction 
 
The terms accuracy and precision are used in the context of measurement. 
Accuracy refers to the degree of conformity and correctness of something when 
compared to a true or absolute value. Precision on the other hand describes the 
variation you see when you measure the same part repeatedly using the same 
device. 
Observer variation is the failure of an observer to measure or identify a 
phenomenon precisely which in turn results in an error. Two types of observer 
variation exist, inter and intra; inter-observer variation is the difference that exists 
between different individuals assessing the same information and intra-observer 
variation is the difference that exists when one individual assesses the same 
information but on more than one occasion.  
Both types of observer variation exist in all aspects of medicine. Clinical oncology as 
a sub-specialty is not immune from observer variation as it relies upon a clinician’s 
own interpretation of clinical and radiological data when making treatment 
decisions. Sources of error in clinical oncology can include the observer missing an 
abnormality i.e. incorrectly identifying the true extent of a patient’s tumour, the 
use of erroneous techniques or imprecise tools resulting in incorrect 
measurements, or simply the misinterpretation of the data itself i.e. misinterpreting 
normal tissues as being abnormal. 
One of the principle tasks clinical oncologists perform in the era of 3D conformal 
radiotherapy is the delineation of the patient’s tumour, termed the target volume, 
and the delineation of normal organs around the tumour, which are termed the 
organs at risk (OAR).  Clinicians delineate these structures on computers using 
radiotherapy treatment planning software. This task is potentially prone to both 
inter and intra-observer variability depending upon the clinical circumstances [1]. 
The first hypothesis of this research is to confirm whether a statistically significant 
difference in inter-observer variation also exists between oncologist’s target 
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volume and OAR contouring within the clinical trial benchmarking period for lung 
and head and neck cancers. This hypothesis will be tested by quantifying inter-
observer variation amongst participating UK head and neck and lung cancer clinical 
oncologists by analysing their pre-trial benchmark QA target volume and OAR 
contours. It also aims to demonstrate that RTQA feedback during the pre-trial 
benchmark period helps to reduce inter-observer variation in target volume and 
organ at risk contours by analysing resubmission benchmark data. 
This research will not assess intra-observer variation as strictly speaking the re-
submissions were not true intra-observer re-assessments but were driven instead 
by specific advice and feedback from the respective trials RTQA teams. 
Recent Advances in Radiotherapy 
Over the last 50 years’ external beam radiotherapy (EBRT) has undergone 
refinement through the discovery of X-ray computed tomography (CT) and 
advances in linear accelerator design. Up until the early 1990s curative external 
beam radiotherapy for cancer patents was typically planned and delivered using a 
2-dimensional technique usually termed ‘conventional radiotherapy’. This 
technique meant that the patient’s underlying cancer and a significant proportion 
of their surrounding normal tissue was encompassed within a typically box shaped 
radiation field. Due to the uncertainties of tumour location and organ movement, 
shielding of normal tissue was relatively minimal. This of course meant that the 
volume of normal tissue treated was great and that patients often developed 
significant acute toxicities [2]. Because of these toxicities patients were often 
unable to tolerate radiotherapy doses more than 67-70Gy when delivered using 
conventional radiotherapy. 
The discovery of CT imaging and its integration into radiotherapy planning during 
the 1980s led to the creation of 3D conformal radiotherapy (3D-CRT) [3]. This term 
describes how the linear accelerator performs complex beam shaping to conform 
the X-rays to match the outline of the patient’s tumour on the patient’s treatment-
planning scan. Conforming the beams also helps to minimise the dose of radiation 
delivered to the patient’s normal organs. 
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Initial studies comparing conventional radiotherapy to 3D-CRT found that 3D-CRT 
helped reduce toxicity whilst maintaining disease control. One phase III randomised 
controlled trial comparing 3D-CRT with conventional radiotherapy using a standard 
dose of 64Gy to treat prostate cancer showed a significant reduction in the dose 
limiting late side effect of proctitis with no impact on disease control when using 
3D-CRT [4]. 
More recent advances in 3D treatment planning software and computer-controlled 
linear accelerators has led to the creation of a high precision form of 3D-CRT 
termed ‘intensity modulated radiotherapy’ (IMRT). Using IMRT, physicists can 
deliver precise radiation doses to a tumour whilst minimising the dose to 
surrounding normal tissues by planning more complex treatments utilising an 
increased number of X-ray beams, sometimes as many as 9. IMRT planning permits 
an even higher level of dose conformity to be achieved. 
The adoption of IMRT and inverse planning techniques has allowed clinicians to 
increase the dose delivered to the patient’s cancer whilst maintaining acceptably 
low doses of radiation to the patient’s normal intracranial, intrathoracic, abdominal 
or pelvic organs. The advent of 3D-CRT, and now more recently IMRT, has helped to 
reduce the incidence of both the acute and late toxicity commonly associated with 
radical radiotherapy. These new radiotherapy treatment techniques have also 
permitted the exploration of dose escalation in the radical treatment of many 
different tumour sub-types. 
The Role of the Modern Clinical Oncologist 
Over the past century, the role of the clinical oncologist has also evolved as a direct 
result of the advances made in radiotherapy planning and delivery. The transition 
from 2D conventional to 3D-CRT planning saw radical changes about the clinical 
oncologist’s role in target volume delineation. Clinicians who bridged this transition 
had to adapt and learn entirely new skills and concepts to be able to fully embrace 
the 3D-CRT era. 
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To help facilitate the transition from conventional 2D to 3D-CRT the International 
Commission on Radiation Units and Measurements (ICRU) published several key 
reports which would define the fundamental concepts of 3D-CRT planning and 
reporting. The reports would be used as benchmarks to standardise the 
terminology and rules used throughout the world to define 3D-CRT [5-7]. By using 
the published ICRU reports as a framework, clinicians could adopt a unified 
approach to 3D-CRT planning and reporting. 
 
 
Figure 1: ICRU 50 / 62 Volume Definitions [8] 
Now because of this evolution, clinical oncologists are tasked with delineating 3D 
target volumes based upon their patient’s own CT planning data. Using the target 
volumes defined in ICRU 50 and 62 clinicians are expected to outline the patient’s 
‘gross tumour volume’ (GTV). The GTV is the primary tumour or other tumour mass 
shown by clinical examination, at examination under anaesthetic (EUA) or by 
imaging. The GTV is classified by tumour staging systems such as TNM (UICC), AJCC 
or FIGO. The tumour’s size, site and shape may appear to change depending on the 
imaging technique used and an optimal imaging method for each tumour site must 
therefore be specified. The GTV may encompass the primary tumour and/or 
involved lymphadenopathy and/or distant metastases. The GTV always contains the 
highest tumour cell density and is absent after complete surgical resection [9]. 
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Any areas considered at risk of subclinical invasion are termed the ‘clinical target 
volume’ (CTV) and will normally encompass the GTV when one is still present (see 
Figure 1 above). The definition of the CTV is based on the histological analysis of 
post-surgical and post mortem tumour specimens. These specimens were analysed 
to determine the extent of tumour cell spread around the gross GTV as described 
by Holland et al. [10]. The GTV-CTV margin is also derived from the biological 
characteristics of the tumour, patterns of local tumour recurrence and the 
experience of the treating oncologist. Manual editing of the CTV margin is therefore 
allowed to account for these factors and anatomical barriers to tumour spread. An 
appropriate margin is then added to the CTV to create a ‘planning target volume’ 
(PTV). The PTV margin accounts for intra and inter-fractional changes in tumour 
size, location, variations in patient positioning and changes in alignment of the 
treatment beams (setup margin).  
Any normal organs within or near to the treatment area should receive as low a 
dose of radiation as possible [6, 7]. These normal organs are termed the ‘organs at 
risk’ (OAR) and change depending upon the site within the patient’s body that is 
being irradiated. The ICRU report described OARs as having distinct tissue 
architectures; serial OARs, for example, the spinal cord, have a high relative seriality 
implying that dose above a tolerance limit, even to a small volume, impairs the 
function of the entire OAR; parallel OARs, for example, the lungs, have a low 
relative seriality where the main parameter impairing the organ’s function is the 
proportion of the OAR receiving a dose above a specified tolerance. In reality 
though, many organs have tissue architecture with both high and low seriality 
components. 
This modern, individualised, three or four-dimensional approach to radiotherapy 
planning now depends heavily on the clinician’s own interpretation of radiological 
cross-sectional anatomy and requires clinicians to differentiate between ‘normal’ 
and ‘abnormal’ body tissues. This of course makes the process of target volume 
delineation highly observer dependent and at significant risk of inter and intra-
observer variation. 
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Variation in CTV delineation by the clinician is the greatest geometric uncertainty in 
the whole treatment process. Studies conducted comparing the outlines of 
radiologists with clinical oncologists have shown significant inter-observer 
variability for both the GTV and/or CTV for multiple different tumour sub-sites. The 
magnitude of this inter-observer variability has also shown to be greater than any 
intra-observer variation [9]. Improvements can be made through training in cross-
sectional anatomy which enables clinicians to distinguish normal structures more 
clearly e.g. blood vessels from lymph nodes, and to identify the extent of structures 
more accurately on cross sectional imaging i.e. the oesophagus on CT or MRI. Joint 
outlining by an oncologist and a radiologist can also help improve consistency and 
the use of consensus guidelines such as the head and neck nodal atlas by Gregoire 
et al. or the pelvic nodal atlas by Taylor et al. can improve the reproducibility of CTV 
delineation significantly [11, 12]. 
Ensuring Quality and Safety in Modern Radiotherapy Delivery 
Modern radiotherapy bears little resemblance to its early form despite relying upon 
the same fundamental scientific principles. Twenty first century practitioners of 
radiation therapy can now use CT plus the possibility of other diagnostic imaging 
technologies to delineate a 3D target which is representative of the patient’s cancer 
whilst observing its relation to the normal tissues surrounding it. With the ability 
now to also integrate real time imaging into the radiotherapy treatment process it 
is now also possible to track the tumour within the patient body to ensure the 
target is not ‘missed’ during the radiation treatment if it moves. 
Consequently, radiotherapy departments now rely upon advanced computer 
technology and highly skilled clinical and non-clinical staff to target and deliver 
radiotherapy treatments. These technological advances though have led to 
increasingly complex processes which in themselves increase the risk of human and 
technological errors. To ensure patients are treated safely and accurately new 
systems and checks have had to be designed to minimise these risks; both 
technological and human. At every point now in the patient’s treatment pathway 
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checks are in place to help minimise error to ensure that patients receive the 
highest quality of care. 
UK hospitals are governed by strict legislation which outlines the safe 
implementation and utilisation of radiation; the Ionising Radiation Regulations 1999 
(IRR 1999) and the Ionising Regulations (Medical Exposure) Regulations 2000 
(IRMER 2000) [13-15]. These regulations define how radiation in the context of 
medicine should be safely managed to ensure patients, public and staff are not 
exposed to radiation unnecessarily. These regulations form the cornerstone of 
radiation protection within UK hospitals. With the ongoing advancement in 
radiotherapy treatment technology and delivery techniques clear guidance is 
needed to ensure clarity within radiotherapy departments internationally. This is 
achieved through regular publications from the International Commission on 
Radiation Units and Measurements (ICRU). Their publications on measurements, 
prescribing, recording and reporting of photon beam therapy ensures unity of 
standards internationally [6, 7, 16, 17]. 
Nationally bodies such as the Royal College of Radiologists (RCR) also play an 
important role in improving modern radiotherapy standards. They have published 
guidance on a variety of important topics aimed at improving UK radiotherapy 
standards; for instance, their publication ‘On Target: Ensuring Geometric Accuracy 
in Radiotherapy’ which explains the significance of systematic and random errors 
typically associated with 3D-CRT radiotherapy. This particular publication provides 
clear guidance on what can be done to minimise errors and improve the accuracy 
and reproducibility of modern radiotherapy delivery [18]. A combination of 
international guidance, national government regulations, published guidance from 
important bodies and the skilled training of hospital staff that provides the basis for 
modern radiotherapy services in the UK. 
Target Volume Delineation Accuracy and Inter-Observer Variation 
With the advent of 3D-CRT and its evolution to IMRT, modern radiotherapy now 
allows us to achieve optimal dose coverage of treatment target volumes. 
Consequently, it is of critical importance that target volumes are delineated 
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accurately to ensure adequate dose coverage whilst minimising dose to normal 
surrounding tissues. Even prior to 3D-CRT, inter-observer variation had been found 
to exist in 2D conventional planning [19]. 
Grabarz et al. conducted a study to describe the degree of inter and intra-observer 
variability in target and field definition when using 3D volume vs. 2D field-based 
planning. The study utilised 9 palliative cases (3 bone metastases, 3 palliative lung 
cases and 3 abdominal pelvis soft-tissue masses) which were given to 5 radiation 
oncologists participating within the study. The radiation oncologists were asked to 
create two sets of treatment fields, one using a 2D field-based approach and the 
second using a 3D volume-based approach. Once created, the 2D and 3D volumes 
were analysed for inter and intra-observer variations in target definition by 
determining the percentage overlap, under-coverage and over-coverage. The study 
found that the degree of inter-observer variation for 2D and 3D planning was 
similar with a degree of overlap of 76% (range 56% - 85%) and 74% (range 55% - 
88%) respectively. Comparison of the 2D and 3D treatment fields defined by the 
same clinicians revealed a mean degree of overlap of 78%; over-coverage was 22% 
and under-coverage, 41%. Statistically there was significantly more under-coverage 
when field-based planning was used for bone metastases (33%) compared with the 
other anatomical sites studied. The author, based on their findings, concluded that 
2D planning is more likely to result in geographic misses in bone metastases 
compared with other areas and that clinically significant inter and intra-observer 
variation exists in palliative radiotherapy planning [19].  
Due to the increased complexity of 3D conformal target volume delineation it 
comes as no surprise that studies examining inter-observer variation during the 3D 
outlining process have found significant inter-observer variation in target volume 
outlines [19-28].  
Wachter et al. examined the benefits of integrating axial and sagittal MRI into 
prostate contouring on CT with the aim of improving localisation of the prostatic 
apex through an inter-observer analysis. The study found that the apex of the 
prostate could be discriminated more easily using the MRI rather than the CT with 
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best judgement seen using the sagittal MRI sequences. The inter-observer variation 
for the definition of the prostate apex was smaller and statistically significant 
(p=0.009) for the sagittal MRI compared to the axial MRI and CT. They concluded 
that the addition of MRI provides superior anatomical information for the purposes 
of target outlining and thereby helps to avoid the unnecessary irradiation of healthy 
tissues [20]. A similar study by Cattaneo et al. looked at target delineation in post-
operative radiotherapy of brain gliomas and the impact image registration of pre-
operative MR on treatment planning CT scans had on inter-observer variability. 
They also concluded that the use of CT and MR registered imaging reduced inter-
observer variability in target volume delineation for post-operative irradiation of 
high grade gliomas and that smaller margins around target volume could be 
adopted in defining irradiation technique [23]. 
A study conducted by Wu et al. looked at inter-observer variation in cervical cancer 
tumour delineation for image-based radiotherapy planning among and within 
different specialties and found that despite the improvements MRI imaging could 
bring to the resolution and definition of anatomical structures there was still 
“human” variations which could overshadow the gains made from these 
technological advancements [21]. The challenges noted for tumour delineation in 
this study included partial voluming by parametrial fat at the periphery of the 
uterus; (2) extension of the tumour into parametrial space; (3) similar signal 
intensity of structures proximal to the tumour such as ovaries, muscles, bladder 
wall, bowel loops, and pubic symphysis; (4) post-radiation changes such as 
heterogeneity and necrosis; (5) susceptibility artefacts from bowels and vaginal 
tampons; (6) presence of other pathologies such as atypical myoma; (7) factors that 
affect pelvic anatomy, including the degree of bladder distension, bowel 
interposition, uterine malposition and retroversion [21]. The conclusion of the 
author, based on their study findings, was that strategies needed to be developed 
for standardization and training in tumour delineation [21]. 
A systematic review conducted by Loo et al. evaluating inter-observer variation in 
parotid gland delineation and its impact on intensity-modulated radiotherapy 
solutions also found that significant inter-observer variation exists in parotid gland 
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delineation in the context of head and neck radiotherapy planning [22]. Their study 
found that almost half of the contours (46%) produced by the participating 
radiation oncologists and radiologists were sufficiently different enough from the 
contour used clinically to have necessitated a different IMRT plan if used. This study 
helps to highlight the impact normal organ outlining can have on radiotherapy 
planning and the study team concluded that strategies, such as consistent 
guidelines, were needed to improve inter-observer consistency in parotid gland 
delineation [22].  
A study by Lorenzen et al. has specifically looked at the impact of guidelines on the 
degree of inter-observer variation in the delineation of the heart and left anterior 
descending coronary artery (LADCA) in the context of breast radiotherapy planning 
[24]. Their study found that common guidelines for the delineation of the heart and 
LADCA helped reduce spatial variation in the heart and length of LAD contoured 
which helped to reduce inter-observer variation and consequently the mean and 
maximum estimated radiotherapy doses to the heart [24]. 
Therefore to help improve both target volume and normal organ delineation 
accuracy and thereby reduce inter-observer variation a number of successful 
strategies have been examined including the use of contrast [29, 30], the use of 
fiducial markers [31], the addition of complimentary imaging modalities such as 
FDG-PET [32] and MRI [33], the aid of a dedicated diagnostic radiologist during 
target volume delineation [30, 34] and the use of protocols which define precisely 
how structures should be accurately delineated [35-37]. These studies have 
revealed that that implementing such strategies can improve target volume 
accuracy and reduce inter-observer variation. Failure though to incorporate such 
strategies has also been shown to impact negatively on patient outcomes and none 
more so than trial protocol compliance. 
The Trans-Tasman Radiation Oncology Group (TROG) 02.02 trial HeadSTART was a 
phase III head and neck chemoradiation study evaluating the potential benefits of a 
new oral radiosensitiser called tirapazamine [38]. The trial was designed to detect a 
10% improvement in overall survival (OS) at 2 years attributable to the 
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tirapazamine. Patients with squamous cell carcinoma of the head and neck were 
randomised to either tirapazamine, cisplatin and radiotherapy or cisplatin and 
radiotherapy alone. The radiotherapy in both arms was to be delivered using 
standard treatment fields and IMRT was not permitted. 
The trial was designed so that once a patient’s radiotherapy planning had been 
completed it was to be submitted to the Quality Assurance Review Centre (QARC) 
for interventional review before the end of the first week of the patient’s 
radiotherapy treatment. The QARC would then provide feedback to the submitting 
centre on whether the plan was compliant with the trial protocol. If not the QARC 
would advise on appropriate modifications to the plan to make it compliant and 
then for the plan to be re-submitted. This system of radiotherapy quality assurance 
(QA) was a semi-prospective one to ensure protocol compliance early in the 
patient’s treatment. Once the patient had completed their radiotherapy treatment 
all the patient’s radiotherapy data was re-submitted for further retrospective 
review by the tumour management group (TMG). 
By the end of the trial, a total of 853 patients had been enrolled and 820 plans were 
available for retrospective review (33 plans were non-evaluable). Of these 74.6% 
(612) were deemed protocol compliant and the remaining 25.4% were judged non-
compliant (208). Of the 208 non-compliant plans, the TMG then assessed whether 
the non-compliance would have any adverse impact on treatment outcome. They 
determined that 53% (111) of the non-compliant plans would have no likely impact 
on treatment outcome but that the remaining 97 plans would have a major adverse 
impact. Of the 97 non-compliant plans 24.7% (24) had incorrect target volume 
definitions, 42% (41) had inadequate tumour dose coverage, 25.8% (25) had 
incorrect dose prescription and 7.2% (7) had excessively prolonged treatment 
schedules. Despite the trial being designed to detect an OS benefit because of the 
addition of tirapazamine, due to the poor radiotherapy protocol compliance there 
was a 20% reduction in OS regardless of randomisation arm. 
The TROG 02.02 trial highlights the importance of protocol compliance and the 
potentially damaging effects poor outlining, poor radiotherapy planning and basic 
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errors in dose prescriptions can have on patient survival. Unfortunately, the TROG 
02.02 trial is not the only one to highlight these problems. More recently Abrams et 
al. showed that in the Radiation Oncology Group (RTOG) 9704 study which looked 
at the potential benefits of chemotherapy and chemoradiotherapy in patients who 
had had resected pancreatic tumours, that deviation from the radiotherapy trial 
protocol resulted in inferior survival in patients [39]. 
Further studies have also revealed that protocol deviations resulting in poor target 
volume delineation can result in increased acute radiation toxicity. On retrospective 
review of the RTOG 0411 trial data it was found that > grade 3 gastro-intestinal 
toxicity was significantly increased in patients who had been treated with major 
deviations from the trial protocol (45% vs. 18%). A breakdown of the major 
deviations revealed that many clinicians were unable to delineate the GTV 
accurately with some GTV’s being >5cm larger than the actual tumour size seen on 
diagnostic imaging [40]. Such findings highlight the importance of accurate target 
volume delineation both in terms of minimising toxicity and maximising treatment 
outcomes. 
The Importance of RTQA and its Role in UK Radiotherapy Trials 
To help ensure cancer patients are treated to the highest standards the ability to 
assess quality of care has become a national priority because deviations from 
accepted standards of care can lead to disparities in the quality of care delivered to 
patients. 
National and International bodies have been tasked with the creation of best 
practise guidelines as well as quality indicators which can be used to monitor the 
quality of radiotherapy practise being delivered e.g. the UK’s National Radiotherapy 
Dataset (RTDS). These radiotherapy quality assurance indicators can also be used to 
help guide the implementation of new radiotherapy techniques into routine clinical 
practice.  
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In terms of radiotherapy clinical trials, deviations from accepted standards of care 
can also have direct and important implications on clinical trial outcomes and can 
potentially confound the question the study has been designed to address. 
A lack of integrated radiotherapy quality assurance within a clinical trial can also 
lead to scepticism surround the trials findings as was demonstrated in the European 
Study Group for Pancreatic Cancer 1 Trial (ESPAC-1 trial) where a lack of robust 
radiotherapy quality control was the focus of much criticism following the 
publication of its results [41]. The ESPAC-1 trial was a phase III, randomised trial of 
adjuvant chemotherapy or chemoradiotherapy for patients who had had pancreatic 
cancers resected. 
The trial reported that adjuvant chemoradiotherapy for resected patients had a 
deleterious effect on overall survival [42]. However, due to criticism of the trials 
radiotherapy quality assurance and the uncertainty this may have had on the 
validity of the trials findings with respect to  chemoradiotherapy, the United States 
National Comprehensive Cancer Network (NCCN) guidelines have not been altered 
to omit recommendations for adjuvant chemoradiotherapy for patients with 
resected pancreatic adenocarcinoma [43]. The ESPAC-1 trial highlights the 
importance radiotherapy quality assurance (RTQA) can have on radiotherapy trial 
outcomes as without it, perceived flaws in radiotherapy quality can hold back major 
practise changes despite statistically significant trial findings. 
A meta-analysis of eight cooperative group radiotherapy clinical trials by Ohri et al. 
and a literature review of seventeen multicentre trials by Fairchild et al. have also 
demonstrated that radiotherapy protocol deviations can have a deleterious effect 
on clinical trial outcomes [44, 45]. As Ohri et. al concludes based on the findings of 
their meta-analysis of four paediatric and four adult multi-institutional radiotherapy 
trials, radiotherapy protocol deviations are associated with increased risks of 
treatment failure and overall mortality [44]. 
Now with a growing weight of international evidence showing the negative 
consequences poor radiotherapy protocol compliance can have on patient 
outcomes it has now become almost mandatory for radiotherapy trials to include a 
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comprehensive package of quality assurance [44-46].  As already mentioned, the 
TROG 02.02 study and others have highlighted the critical impact of protocol 
compliance on the treatment of advanced head and neck cancers. The TROG 02.02 
study showed that major deficiencies in radiotherapy treatment plans resulted in a 
20% decrease in overall survival regardless of randomisation arm [38].  
In the United Kingdom (UK) the National Cancer Research Institute (NCRI) 
Radiotherapy Trials Quality Assurance (RTTQA) Group has been tasked with 
ensuring that all participants in NCRI badged trials adhere to the relevant trial 
protocol [47]. The RTTQA group achieves this through a program of activities 
tailored towards the clinical trials objectives. Since its inception, the RTTQA group 
has developed its program of QA activities to account for new techniques and 
advances in planning and delivery systems. When first established the focus of trial 
QA was predominantly treatment machine focused but over the past decade this 
has developed to include all aspects of radiotherapy delivery from target volume 
delineation to IMRT verification. Before a centre can participate in a UK NCRI trial 
they are required to complete all steps of the trial specific RTTQA accreditation 
process. This accreditation process now typically includes pre-trial benchmark 
outlining cases which have been designed to ensure clinicians are following the 
guidance set out in the trial protocol. 
The addition of pre-trial benchmark cases to the activities performed by the RTTQA 
group has meant that new systems have had to be developed to robustly assess 
participating trial centres prior to trial patient recruitment. These robust systems 
have been designed to ensure participating clinicians meet the minimum standards 
of target volume delineation for that trial. To this end, the pre-trial benchmark 
cases are focused upon ensuring clinicians can achieve a minimum standard and 
consequently all modern NCRI trials have adopted this strategy. 
In the UK, all NCRI trial pre-trial benchmark cases are available for download from 
the RTTQA’s website. All centres wishing to participate in a trial are expected to 
download and complete them before they are permitted to recruit patients into the 
trial. Once a centre has submitted their completed cases for review they are 
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assessed by the trials own QA team which typically comprises of one or more 
expert clinicians from the trials TMG plus one or more members of the RTTQA 
group who have been assigned to oversee the QA specific activities of the trial. The 
duties of the QA team include ensuring that the submitting clinician has followed 
the instruction contained within the outlining protocol to construct their target 
volumes and normal tissue structures. If after review by the QA team it is felt that 
improvements could be made, then constructive feedback is produced by the QA 
team and sent back to the trial centre to help them re-evaluate their contours prior 
to them re-submitting them. This process is normally repeated until it is felt by the 
central QA team that the centre has met the minimum QA requirements of the trial. 
Measuring Target Volume and Normal Tissue Inter-Observer Variability 
In the past, most UK pre-trial outlining benchmark case assessments were 
performed by direct visual inspection of all submitted contours by the central QA 
team. More recently a system of pre-trial benchmark quality assurance utilising a 
‘gold standard’ contour set has been adopted. This method relies upon the creation 
of reference set of contours termed the ‘gold standard’. These ‘gold standard’ 
reference contours can be created in either one of two ways; either by an expert 
individual or through the consensus agreement of a panel of expert clinicians [48-
53]. This latter technique now seems to be the more common method of defining 
the reference or ‘gold standard’ contours although the former method continues. 
The benefit of having a pre-defined set of reference contours is that all submitted 
pre-trial benchmark contours can now be quickly and easily compared against the 
reference set either visually or using more advanced computer software which can 
measure different conformity indices. 
Conformity indices (CIs) are numerical metrics calculated using mathematical 
formulae which define concordance based on variations in volume and spatial 
relationships [54]. Simply put they are a measurement of the common volume 
included in 2 volumes or a comparison of a common or consensus volume of 
several volumes with each of the constituent volumes [27]. 
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A systematic review looking at the geometrical analysis of radiotherapy target 
volume delineation conducted by Hanna et al. in 2010 found a total of 63 published 
studies which used either simple volume metrics or CIs to compare target volumes. 
The review found that the majority of published studies (84%) relied upon simple 
volume measurements when comparing target structures and only 30% of the 
studies utilised CIs when comparing radiotherapy volumes [55]. 
The problem with simple volume measurements is that unlike CIs they do not give 
you any information on the spatial relationship between two volumes i.e. the 
common volume included in both radiotherapy volumes. The spatial relationship 
between two volumes; where A is, the investigator outline and B is the gold 
standard outline, can be analysed in several different ways depending upon the CI 
used. 
The most common CI metric used in volume analysis is the concordance index 
which is also known as the Jaccard similarity coefficient or Jaccard conformity index 
(JCI) [55-57]. The JCI is the ratio of intersection of two volumes, as compared with 
the union of the two volumes under comparison: 
 
JCI (Concordance Index) = AB 
       AB 
 
The Jaccard Index can be reported as a fraction or as a percentage if multiplied by 
100 [55]. Other commonly used CIs are the Dice Coefficient (DC) [55], van’t Riet 
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Index [58], Discordance Index (DI) [59] and Geographical Miss Index (GMI) [60]. The 
DC and Van‘t Riet indices assess for variations in under and over outlining. 
 
Dice Coefficient (DC) = 2(AB) 
   A + B 
 
Van ‘t Riet Index = AB x AB 
                                 A          B 
 
The DI is useful in assessing over outlining and conversely the GMI is useful in 
determining the extent of under outlining: 
 
For ‘over outlining’ you can use the Discordance Index (DI) = 1-(AB) 
      A 
 
For ‘under outlining’ you can use the Geographical Miss Index (GMI) = B-(AB) 
          B 
 
Evaluation of Parameters for Quantifying Inter-Observer Variability in Target 
Volume Definition 
Currently there are a large selection of parameters which can we used to evaluate 
inter-observer variability within the context of radiotherapy clinical trials. These 
parameters can be classified into three main group according to their methodology 
[61]. 
The first group contains descriptive parameters which describe the distribution of 
volumes, such as average or mean (if normally distributed), median or mode (if 
non-normally distributed), standard deviation, standard error, range of volumes or 
maximum or minimum volumes [62], ratio of the largest volume to the smallest and 
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dispersion of the distribution i.e. coefficient of variation (COW). These simple 
volume assessments are easy to measure, and relatively free from interpretation 
bias. Simple volume parameters also have the advantage of producing continuous 
variables that are amenable to statistical analysis and parametric and non-
parametric calculations [55]. 
The second group contains parameters which deal with measures that describe the 
area of overlap between contoured volumes and includes the Jaccard index, 
discordance index (DI), geographical miss index (GMI), Dice coefficient and Van‘t 
Riet Index. Due to the large number of available metrics, this second group of 
parameters is the one where harmonisation in reporting is lacking [61]. It is also the 
group of parameters which reported studies seem use to quantify inter-observer 
variability in target delineation most often [62-73]. Parameters within this group 
can also be selected to assess specific variances between contoured volumes such 
as under (GMI) or over outlining (DI). The advantage of the parameters in this group 
is that they provide a single measurement of volumetric and positional change but 
are therefore prone to missing subtle areas of variation within a volume and have 
been shown to correlate poorly with length.  
The second group also contains parameters which can be used to assess 3D 
structures and the volume of displacement in space i.e. variation of the centre of 
mass (COM). Such parameters rely upon the reconstruction of surface points on the 
base of meshes and then utilise 3D vectors to represent the differences on the 
surfaces of structures which permits the exact topographical identification and 
visualisation of disagreements [67, 69, 74-79]. A centre of mass analysis is useful for 
describing displacements or differences in locations of volumes but is unhelpful for 
the comparison of volume size. It is theoretically possible that two volumes under 
comparison could have the same centre of mass but different simple volume 
measurements (see Figure 2 below). 
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Figure 2: Two Volumes with Different Sizes but The Same Centre of Mass 
The third group contains parameters which utilise statistical measures of 
agreement such as intraclass correlation coefficients (ICC), κ statistics (Fleiss or 
Cohen) or other reliability analysis tools [29, 52, 63, 67, 73, 80-82]. The κ statistics 
can be utilised to measure the magnitude of agreement between either two 
outlines (Cohen Kappa) or multiple outlines (Fleiss’ Kappa). The measure calculates 
the degree of agreement in classification over that which would be expected by 
chance. Fleiss' kappa can be used only with binary or nominal-scale ratings and 
Cohen's kappa coefficient is a statistic which measures inter-rater agreement for 
qualitative (categorical) items. For both Fleiss and Cohen Kappa statistics, there is 
no information on the direction of the error and both require a decision made on 
what level of agreement is acceptable. Table 1 below summarises the commonest 
used parameters from each group. 
Based on published reviews of different comparison methods used to assess 
radiotherapy target volume delineation there does not seem to be a perfect 
parameter which fully characterises geometrical volume differences, positional 
changes and inter-observer variability [55, 61]. Instead, each comparison method 
seems to offer distinct advantages and disadvantages and should be selected based 
upon the focus of the research. Hanna et al. recommends combining a simple 
volume parameter with a parameter that measures positional displacement, such 
as the centre of mass or the concordance index [55] whilst Fotina et al. recommend 
adding a further statistical measure of agreement to permit full reporting of the 
variability in delineation. 
Conformity Indice 
Name 
Description of Metric Advantages Disadvantages 
Jaccard Conformity 
Index (JCI) 
 
Van’t Riet 
 
Dice Coefficient 
• Ratio of the volume of 
overlap of two structures 
over union volume of the 2 
structures 
• Widely used in 
literature for multiple 
tumour sites and with 
different imaging 
modalities 
• Includes errors of over 
and under-outlining 
• Benchmark level 
defined for poor 
concordance (breast 
cancer) 
• Whole volume metric, may miss 
areas of variation within the volume 
• Summary metrics incorporating both 
over- and under-outlining errors 
• Concordance will increase with larger 
volumes 
• Correlates poorly with length 
• Failure to detect small but potentially 
clinical significant anatomical errors 
such as the bronchus in the SCOPE 1 
pre-trial test case 
• No information on the direction of 
the error 
Geographical Miss Index 
(GMI) 
• Calculates amount of under-
outlining  
• Calculates amount of 
geographical miss i.e. 
under-outlining 
• Well correlated with volume 
• No benchmark for comparison, 
tumour site and case dependent 
Table 1: Detailed Information on Conformity Indices Used in Comparing Radiotherapy Target Volumes [54, 55] 
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Conformity Indice 
Name 
Description of Metric Advantages Disadvantages 
Discordance Index (DI) • Calculates amount of over-
outlining 
• Calculates amount of 
over-outlining 
• Well correlated with volume 
• No benchmark for comparison, 
tumour site and case dependent 
Kouwenhoven Index • Ratio of the volume of 
overlap of two structures 
over union volume of the 2 
or more structures 
• No reference volume 
required for calculation 
• Value dependent on conformity to 
other investigators and not with gold 
standard 
Kappa Statistic (Fleiss) • Measurement of magnitude 
of agreement between 
multiple outlines 
• No reference volume 
required for calculation 
• Objective benchmark 
values to assess 
agreement 
• Value dependent on investigators 
and not with gold standard 
• Only valid for multiple investigator 
outlines 
• Decision required about what level of 
agreement is acceptable 
• No information on the direction of 
the error 
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Conformity Indice 
Name 
Description of Metric Advantages Disadvantages 
Kappa Statistic (Cohen) • Measurement of magnitude 
of agreement between two 
outlines 
• Can be used to compare 
two outlines e.g. 
investigator volume and 
reference volume 
• Objective benchmark 
values to assess 
agreement 
• Not been previously used to assess 
outlining variation  
• Decision required about what level of 
agreement is acceptable 
• No information on the direction of 
the error 
Mean Distance to 
Conformity (MDC) 
• Shape based statistic that 
measures the mean 
displacement needed to 
transpose every voxel in the 
investigator volume onto the 
reference volume 
• Gives measurements of 
variation (in mm) 
• Has an over and an 
under-outlining 
component 
• Independent of size of 
volumes under 
comparison 
• Over and under-outlining MDC 
values that are high in one direction 
could cancel each other out 
• Use of the under and over-outlining 
MDC results in two metrics, 
offsetting the advantages of a single 
metric to describe outlining 
• No information on the direction of 
the error 
• Correlates poorly with length and 
volume 
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Inter-observer Variation in the Context of UK Radiotherapy Trials 
Now for over a decade the UK’s RTTQA group has been instrumental in the 
administration of quality assurance for national UK radiotherapy trials. 
Consequently, it has collated a substantial repository of pre-trial benchmark case 
data from multiple different UK centres participating in multiple different UK 
radiotherapy trials. Given the growing weight of international evidence highlighting 
the importance of target volume outlining on patient outcomes this data holds a 
wealth of important information on the degree of observer variability that exists 
amongst UK Clinical Oncologists in the context of clinical trials. Work evaluating 
inter-observer variability in GTV delineation in the context of upper and lower 
gastro-intestinal (GI) tumour sub-sites has already been conducted thorough the 
analysis of the SCALOP, ARISTOTLE, NEO-SCOPE and SCOPE 1 pre-trial benchmark 
case [83-86]. 
The National Cancer Research Institute SCOPE 1 trial was a phase II/III randomised 
controlled trial of chemoradiation with capecitabine and cisplatin with or without 
cetuximab for oesophageal cancer. Prospective trial centres were required to 
complete a mid-oesophagus pre-trial benchmark case with the help of a 
comprehensive radiotherapy outlining protocol. A total of 50 investigators drawn 
gross tumour volumes were received from 34 UK oncology centres and these were 
analysed against a pre-defined gold standard GTV to determine several different CIs 
(JCI, GMI, and DI). The SCOPE I data revealed a median JCI for investigator GTV’s of 
0.69 (interquartile range, 0.62 – 0.70) with 14 of 50 investigators (28%) achieving a 
JCI of 0.70 or greater [83]. The SCOPE I JCI values were comparable with those 
published in three different studies who had JCI values ranging between 0.69 – 0.72 
[87-89]. 
Through the course of the SCOPE 1 GTV analysis a new metric termed the local 
conformity index (L-CI) was established. Unlike traditional CIs which analyses the 
structure of interest the L-CI analysed the structure on each individual CT slice and 
can highlight individual CT slices where GTV discordance was greatest [27]. Gwynne 
et al. found that the highest levels of discordance (<20% of investigators achieving a 
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L-JCI ≥0.70) was seen on four CT slices and was now able to directly review these 
slices for an underlying reason. What they found was a mixture of under outlining 
of the oesophageal wall and inappropriate inclusion of the azygous vein, 
pericardium, bronchus or peri-bronchial tissues which they concluded was due to 
misinterpretation of normal anatomy [27]. 
Normal Tissue Outlining in the Context of UK Radiotherapy Trials 
So far, most published research involving UK radiotherapy trials has focused on the 
extent of inter-observer variation concerning the gross tumour volume [64, 90-93]. 
Comparatively, much less work has been conducted on inter-observer variability 
involving normal tissue outlining [22]. 
Analysis of the SCOPE 1 data revealed that clinicians were misinterpreting normal 
tissues seen on CT as viable tumour tissue. This raises the question as to the extent 
of inter-observer variation and radiological misinterpretation which is also taking 
place when clinicians outline the normal anatomical structures on the CT planning 
scan. These normal organs can have an important bearing on the radiotherapy 
planning process as Loo et al. demonstrated when they conducted a systemic 
review evaluating inter-observer variation in parotid gland delineation and its 
impact on intensity-modulated radiotherapy solutions [22]. Loo et al. found that 
almost half of the contours (46%) produced by the participating radiation 
oncologists and radiologists were sufficiently different from the contour used 
clinically to have necessitated a different IMRT plan if used [22]. Therefore, bearing 
in mind the constraints of these normal tissues can dictate the optimal 
radiotherapy plan selected, poor outlining of normal tissue structures could 
potentially have a direct impact on the quality and outcome of a patient’s 
treatment. 
Assessment of Target Volume and Normal Tissue Structures in The Context of UK 
Head and Neck and Lung Cancer Radiotherapy Trials 
The first hypothesis for this research is that there is a statistically significant inter-
observer variation amongst clinical oncologist’s target volume and OAR contours 
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within the context of the pre-trial quality assurance (QA) benchmark cases for four 
different UK radiotherapy trials. The second hypothesis is that RTQA feedback 
during the pre-trial benchmark period improves head and neck clinician contouring. 
This research tests the first hypothesis by establishing whether any statistically 
significant inter-observer variation exists amongst UK head and neck and lung 
cancer oncologists by analysing their target volume and OAR contours submitted 
via the pre-trial benchmark QA cases. 
The second hypothesis has been tested by establishing whether RTQA team 
feedback significantly impacts on UK head and neck oncologists target volumes and 
OAR contours during the pre-trial benchmark QA period. 
This work will analyse the pre-trial benchmark cases of the ART-DECO, COSTAR, 
IDEAL and i-START trials. It will also analyse the re-submissions contours from the 
ART-DECO and COSTAR trials. 
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Chapter 2: Materials and Methods 
 
Overview of the Head and Neck and Lung Cancer Trials Selected for Analysis 
To investigate the degree of inter-observer variability which exists amongst clinical 
oncology consultants routinely outlining head and neck and lung cancer target and 
organs at risk volumes four national radiotherapy trials were selected which require 
clinicians to complete pre-trial outlining benchmark cases. The two head and neck 
trials selected were the ARTDECO (Accelerated Radiotherapy sTudy of Dose 
EsCalated intensity-mOdulated radiotherapy versus standard dose intensity-
modulated radiotherapy in patients receiving treatment for locally advanced 
laryngeal and hypopharyngeal cancers) and the COSTAR (COchlear Sparing inTensity 
modulAted Radiotherapy versus conventional radiotherapy in patients with parotid 
tumours) trials. The ARTDECO trial is evaluating dose escalated, accelerated (total 
dose of radiation is given over a shorter period (fewer days) compared to standard 
radiation therapy), IMRT versus standard dose IMRT in patients receiving treatment 
for locally advanced laryngeal and hypopharyngeal cancers. The COSTAR trial is 
evaluating the potential toxicity benefits of cochlear-sparing IMRT versus 
conventional radiotherapy in patients with parotid tumours. 
The two lung cancer trials selected were the IDEAL (Isotoxic Dose Escalation and 
Acceleration in Lung Cancer ChemoRadiotherapy) and i-START (ISoToxic Accelerated 
RadioTherapy in locally advanced non-small cell lung cancer) trials. The IDEAL trial 
was evaluating the toxicity, feasibility and potential clinical effectiveness of isotoxic, 
dose-escalated radiotherapy with concurrent chemotherapy versus standard 
chemoradiotherapy in patients with stage II or stage III non-small cell lung cancer 
(NSCLC). The method of dose escalation in IDEAL was through an individual patient-
based model. Each patient would be treated to the dose that, based on the 
optimised distribution of radiation on his/her treatment plan, was calculated to be 
associated with an acceptable level of grade three toxicity (from oesophagus or 
lung). In this way, each patient would be treated to the highest acceptable dose for 
his/her own situation and would not be exposed to excess risk with the 
introduction of a generic high-dose to the whole population. This method of 
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individualised dose escalation using predefined normal tissue constraints is termed 
isotoxic radiotherapy e.g. one patient receives 66Gy, another 74Gy based upon the 
maximum safe achievable dose to the patient which remains within the bounds of 
the pre-defined normal tissue constraints for those critical organs surrounding the 
target volume. For instance, in thoracic radiotherapy, this includes the mean lung 
dose (MLD), the oesophagus and the spinal cord.  
The i-START trial was designed to determine the highest doses of radiotherapy that 
could be safely delivered in locally advanced NSCLC and would evaluate the 
feasibility of delivering isotoxic, accelerated radiotherapy in the treatment of 
patients with stage II to stage IIIB NSCLC. 
Overview of the Pre-Trial Outlining Quality Assurance (QA) Program 
For all four trials, normally one consultant clinical oncologist in each participating 
centre is designated the principle investigator (PI) and it is their duty to act as the 
local lead for the trial in their centre. All the selected trials required the local PI to 
complete pre-accrual contouring benchmark cases. The purpose of the benchmark 
cases was multifactorial. Firstly, to ensure that the PI was correctly following the 
contouring guidelines contained within each of the trials outlining protocols, 
secondly to ensure the correct nomenclature was being used to define the volumes 
and finally to ensure that target volume geometric expansion was done correctly 
and using reasonable expansion margins.  
Trial pre-accrual benchmark cases were available for download from their 
respective webpage on the Radiotherapy Trials Quality Assurance (RTTQA) website 
(http://www.rttrialsqa.org.uk/). Each case consisted of a compressed DICOM CT 
data set. DICOM is an acronym for Digital Imaging and Communications in Medicine 
which is a standard for handling, storing, printing, and transmitting information in 
medical imaging. Participating clinicians were instructed to extract and import the 
DICOM data into their centres radiotherapy treatment planning system (TPS). This 
allowed the trial PI to complete the outlining cases using the planning software they 
would normally use to plan their patients. In the case of the IDEAL and i-START trials 
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clinicians were also able to download the diagnostic PET scans relevant to each of 
the two cases to assist with target volume delineation. 
When completing the contouring cases, PI’s were expected to refer to the 
appropriate trial protocol because it contained a clinical history for each contouring 
case, diagnostic radiology findings for the cases, definitions of target volumes and 
critical structures, guidance on delineating target volumes and some normal 
structures, and guidance on structure naming and nomenclature. 
ARTDECO and COSTAR Trial: Outlining QA Program 
The ARTDECO trial requires PI’s to complete two pre-trial benchmark contouring 
exercises; the first a squamous cell carcinoma of the larynx case and the second a 
squamous cell carcinoma of the hypopharynx case. For the COSTAR trial PI’s were 
required to outline a single case which was the post-operative bed and elective 
nodes of a 53-year-old female who had undergone surgery for a right sided high-
grade ex-pleomorphic adenoma of the parotid gland. Both the ARTDECO and 
COSTAR trial protocols stipulated which target and normal organ structures needed 
to be contoured. 
The ART-DECO target volume delineation and planning guidelines contained 
anatomical illustrations for each head and neck subsite, nodal atlas, and step-by-
step instructions detailing how the GTV, CTV and PTV contours should be 
constructed. Aside from detailing which normal organs should be contoured for 
each case (spinal cord, brainstem, contralateral parotid and ipsilateral parotid) no 
further information regarding delineation was provided.  
The COSTAR target volume delineation and planning guidelines also contained 
illustrations detailing the anatomy of the parotid gland, guidance on nodal 
outlining, and step-by-step instructions detailing how the parotid bed (CTV) and 
PTVs should be constructed. Clinicians were instructed to outline both cochlea, 
contralateral parotid gland, spinal cord (below foramen magnum), brainstem 
(above foramen magnum) and lens. The COSTAR guidelines included definitions to 
aid correct outlining of the brainstem and spinal cord; the brainstem was defined as 
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beginning at the level of the foramen magnum and outlining of the structure should 
extend sufficiently superior to continue beyond the limit of irradiating fields. The 
spinal cord was defined as beginning below the level of the foramen magnum and 
extending inferiorly to the manubrium. Clinicians were also asked to contour the 
spinal cord and not the spinal canal. Prospective COSTAR PI’s were expected to 
follow these instructions to help standardise spinal cord and brainstem outlines. 
Once the prospective PI had completed the benchmark outlining cases for either 
the ARTDECO or COSTAR trials then their contours were transmitted back to the 
respective central QA team for that trial. Once received, the trial QA team would 
perform an assessment of the submitted contours using the trial protocol and the 
tumour management group’s (TMG) reference contours for that benchmark case. 
The TMG reference contours were consensus contours drawn from the collective 
agreement of the clinicians who sit on the trial management group. Example 
images taken from the ARTDECO and COSTAR TMG consensus contours can be seen 
in Figure 3, Figure 4 and Figure 5. 
IDEAL & i-START Trials: Outlining QA Program 
The IDEAL and i-START trials both share the same pre-trial benchmark outlining 
exercises. Again, both trials required prospective PI’s to contour two pre-trial 
benchmark outlining exercises. Both clinical cases were locally advanced, stage III 
lung cancers with tumours located centrally within the chest. To aid clinicians 
background case histories, the diagnostic imaging (CT plus PET) with the reports 
were provided along with the planning CT scan. The IDEAL / i-START outlining 
instructions requested clinicians to create structures to represent the body, GTV, 
CTV, PTV, left lung, right lung, the total lung minus the GTV volume, spinal cord, 
heart and oesophagus. The IDEAL trial planning and delivery guidelines (which the 
pre-trial benchmark cases advised clinicians to reference) contained target and 
normal organ delineation instructions. Clinicians were given guidance on how to 
define the GTV, CTV, PTV, lungs (these should be segmented in every slice from the 
apex to the base as a paired organ), oesophagus (defined as a solid organ 4cm 
above and 4cm below the PTV; if a 4cm margin is not possible inferiorly then the 
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gastro-oesophageal junction will determine the inferior limit of segmentation), 
spinal cord (defined as the spinal canal 4cm above and 4cm below the PTV) and 
heart. Prospective trial PI’s were therefore expected to follow the guidance 
contained within the planning and delivery protocol to help standardise target 
volume and OAR outlining. 
As with the ARTDECO and COSTAR trials, once the prospective IDEAL or i-START trial 
PI had completed the benchmark outlining cases their contours were transmitted 
back to the IDEAL / i-START QA team for contour analysis. The contour assessment 
was performed using the trial protocol and the TMG reference contours. Again, the 
TMG reference contours were contours drawn from the agreement of the clinicians 
who sit on the trial management group. Both the IDEAL and i-START trials had their 
own reference contours for prospective PI contour analysis. Example images taken 
from the IDEAL TMG consensus contours can be seen in Figure 6 and Figure 7. 
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Figure 3: Example CT Slice from ARTDECO Contouring Exercise 1 Displaying TMG Reference Contours (turquoise = body contour; 
light purple = CTV1 (high dose volume); brown = CTV2 (low dose volume); yellow = spinal cord; green = right parotid gland; pink = 
left parotid gland; dark purple = brainstem). 
Page | 41  
 
 
Figure 4: Example CT Slice from ARTDECO Contouring Exercise 2 Displaying TMG Reference Contours (orange = body contour; dark 
red = GTV; yellow = CTV1 (high dose volume); light blue = CTV2 (low dose volume); light red = right parotid gland; purple = left 
parotid gland; brown = spinal cord; green = brainstem) 
Page | 42  
 
 
Figure 5: Example CT Slice from COSTAR Contouring Exercise Displaying TMG Reference Contours (orange = CTV1 (high dose 
volume); yellow = CTV2 (low dose volume); blue = spinal cord; purple = left parotid gland; red = brainstem) 
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Figure 6: Example CT Slice from IDEAL / i-START Contouring Exercise 1 Displaying IDEAL Reference Contours (dark yellow = body; 
green = GTV, dark red = CTV, turquoise = PTV; dark purple = oesophagus; light yellow = spinal cord; blue = spinal cord PRV; light red 
= heart; light purple = right lung; brown = left lung) 
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Figure 7: Example CT Slice from IDEAL / i-START Contouring Exercise 2 Displaying IDEAL Reference Contours (dark yellow = body; 
green = GTV, dark red = CTV, turquoise = PTV; dark purple = oesophagus; light yellow = heart; blue = spinal cord PRV; light red = 
spinal cord PRV; light purple = right lung; brown = left lung)
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Overview of the Assessment Process Used in the Pre-Trial QA Program 
All pre-trial outlining benchmark exercises submitted for assessment were first 
reviewed by the respective trials QA team for trial protocol outlining compliance. 
The TMG’s reference contours were then used as a visual benchmark to assess 
whether the contours submitted adequately delineated the target volumes and 
OARs stipulated in the contouring exercise instructions. 
In the context of the head and neck trials, if the RTQA team felt that the target 
volumes or OAR structures were unsatisfactory due to deviations from the outlining 
protocol, then the submitting clinician was requested to resubmit their contours 
following guidance set out in the RTQA team’s feedback report. Once resubmitted, 
the cases were then re-reviewed for protocol compliance and further resubmissions 
requested until judged trial protocol compliant. An analysis of the impact of this on 
clinician outlining can be found in Chapter 5. 
Data Analysis Step 1: Data Collection and Processing 
I collected all benchmark cases, including resubmissions, for ARTDECO and COSTAR 
up until June 2012 in DICOM format. For the IDEAL and i-START trials, I collected all 
submitted benchmark cases in DICOM format up until November 2012. 
Before any of the submitted DICOM data could be analysed all the structure names 
contained within the submitted cases had to manually checked and edited by me to 
ensure consistent structure naming; approximately 1000 individual structures in 
total. 
This time-consuming step was necessary because the conformity analysis tool 
required all the same structures to be labelled in the same way i.e. ‘CTV1’ and not 
‘CTV_1’ or ‘CTV-1’; ‘Brainstem’ and not ‘Brain_Stem’ or ‘BS’. Without me 
performing this important step the analysis tools would not have been able to 
analyse all the submitted structure contours as it would not have recognised many 
of them due to inconsistent structure nomenclature.  
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Data Analysis Step 2: Analysis of Pre-Trial Benchmark Cases 
Once the data had been processed to ensure uniform structure nomenclature it 
was then analysed using a conformity analysis tool built by Dr Emiliano Spezi using 
MATLAB R2011a and CERR v.4.0 by.  All submitted cases were analysed against their 
respective trial management group (TMG) consensus contours to assess for inter-
observer and intra-observer variation. The conformity analysis tool calculated the 
volume of each structure then the Dice coefficient (DC), Jaccard index (JI), 
geographical miss index (GMI) and RIET index for each structure by comparing it 
directly to its comparative TMG reference structure. To facilitate easy comparison 
of all 4 output indices, 1-GMI was also calculated.  
The conformity analysis tool also calculated the Local Conformity Index (L-CI) for 
each structure. This metric was created following analysis of the SCOPE 1 pre-trial 
benchmark case GTV structures. Unlike traditional conformity indices which 
analyses the structure of interest the L-CI analyses the structure on each individual 
CT slice and can help highlight where discordance is greatest within each contoured 
structure on an individual CT slice basis. 
Data Analysis Step 3: Collation of Output Structure Analysis Data 
Once the conformity analysis tool had finished calculating the data it was output as 
comma-separated values files (.CSV files) which Microsoft Excel 2016 recognises as 
a single column of numerical values contained within a spreadsheet with each row 
within the Excel spreadsheet representing a different submitting clinician. The 
analysis tools created a .CSV file for every indice measured for every structure 
analysed. In total 1609 individual .CSV files were created for all the structures 
analysed. For the purposes of further analysis, I collated the data from each .CSV 
file into Microsoft Excel 2016 spreadsheets. 
To permit statistical analysis of inter-observer variation within the output data, the 
analysed head and neck trial and lung trial structures were grouped into three 
different categories: 
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1. Targets (which included CTVs) 
2. Serial OARs (which included spinal cord, brainstem and oesophagus) 
3. Parallel OARs (which included parotid glands, heart and lungs) 
Data Analysis Step 4: Statistical Analysis of the Conformity Indice Data 
Once all the data had been collated in Excel 2016, it was then analysed using 
MATLAB to look for statistically significant differences to determine whether the 
proposed hypotheses were valid. 
Submission structures from all the trials were sorted into three distinct groups – 
target structures (which included the high dose CTV); serial organs at risk (which 
included spinal cord, brainstem and oesophagus) and parallel organs at risk (which 
included the parotid glands, lungs and heart). The organs contained within each 
respective serial or parallel group were determined using the radiobiological 
definitions of parallel and serial organs. The term parallel organ is based upon an 
analogy with electrical circuits and can be contrasted with serial organs. A parallel 
organ, like the parotid gland, has redundancy built in, and a certain fraction of the 
organ parenchyma (or functional subunits) can be sacrificed and the organ will still 
maintain its function albeit reduced. Classic serial organs are the spinal cord and 
oesophagus where loss of function will occur if even a small length of either 
structure is sacrificed; typically, serial organs are tubular structures and therefore 
cylindrical in shape. 
Using these definitions, the target structure group contained the volumes which 
clinicians had defined as containing either the primary tumour, or areas at high risk 
of containing residual tumour cells. The parallel organs at risk group contained 
those critical organs which are defined within the context of radiotherapy planning 
as being parallel i.e. parotid glands, lungs and heart (although the heart organ does 
contain serial tissues and can therefore be considered a serial-parallel organ). The 
serial organs at risk group contained critical organs which are defined within the 
context of radiotherapy planning as being serial i.e. spinal cord, brainstem and 
oesophagus. Parallel and serial organs also differ geometrically as serial organs are 
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normally tubular shaped structures whereas parallel organs are often more 
complex in their anatomical shape. Therefore, the organ at risk groupings used for 
the purposes of analysis could be considered to reflect those with more complex 3D 
structures (parallel organs) and those with simpler tubular shapes (serial organs). 
For hypothesis one this was tested using a paired difference test with Bonferroni 
correction. A paired difference test is a type of location test that is used when 
comparing two sets of measurements to assess whether their population means 
differ. A paired difference test uses additional information about the sample that is 
not present in an ordinary unpaired testing situation, either to increase the 
statistical power, or to reduce the effects of confounders. A Bonferroni correction 
was utilised to counteract the problem of multiple comparisons. The results of 
these analyses are detailed in Chapters 3 and 4. 
For hypothesis two, a paired t-test was utilised. A paired t-test is a statistical 
technique that is used to compare two population means in the case of two 
samples that are correlated. This test seemed most appropriate for detecting 
possible statistical differences between the first and final contouring submissions. 
Data Analysis Step 5: Designing an Innovative Solution for Collating L-CI Structure 
L-Data 
In the case of the structure L-CI data, because of its complex nature an innovative 
method of consolidating it was needed which would allow an easy and rapid visual 
interpretation of its findings. My solution to this problem was to create a bespoke 
spreadsheet for each structure analysed from each benchmark case using Microsoft 
Excel 2016. How this was done is detailed in Appendix 1 and by using this method, 
it was then possible to quickly visualise where the greatest variation existed in 
clinician target and OAR contouring and therefore useful in interpreting the 
individual Dice, Jaccard, Van’t Riet and GMI indices and the statistical analysis of 
their findings. 
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Chapter 3: Results of Inter-Observer Variation Analysis Between Target 
Volume, Serial and Parallel OAR Outlines Within Two Head and Neck 
Clinical Trials 
 
I collected all the pre-trial benchmark cases for the ARTDECO and COSTAR trials up 
until June 2012 in DICOM format. In total 288 first submission structures were 
analysed from both trials based upon three distinct groups – target structures 
(which included the high dose CTV); serial organs at risk which (included spinal cord 
and brainstem) and parallel organs at risk (which included parotid gland). Details of 
these grouping are summarised in Table 2 below. 
 
Group Name 
Structures 
Included in 
Group 
Number of 
Structures 
Analysed 
Total 
Target 
Structures 
(TARGET) 
CTV1 
(high dose CTV) 
63 63 
Serial Organs 
(OAR-S) 
Spinal Cord 63 
126 
Brainstem 63 
Parallel Organs 
(OAR-P) 
Left Parotid 63 
99 
Right Parotid 36 
Table 2: Summary of COSTAR and ARTDECO Target and OAR Contour Groupings 
 
Descriptive statistics are summarised for the DICE, JACCARD, RIET and 1-GMI 
indices for each respective group in Table 3. The mean index value shown in column 
two of Table 3 is the numerical measure of conformity for each indice analysed. This 
is a numerical scale between 1.0 and 0 where 1.0 represents perfect conformity and 
0 no conformity. Hence the closer the mean index value is to 1.0 the better the 
conformity between the structures analysed and conversely, the closer to 0 the 
worse the conformity. 
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The boxplot as shown in Figure 8 demonstrates that overall it seems the target 
contours (CTV1 – which contained the high dose CTV) had the highest conformality, 
followed by the serial organs at risk (spinal cord and brainstem) and then finally the 
parallel organs at risk (parotid glands) for all four conformity indices measured.   
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Number 
of 
contours 
Mean 
Index 
Value 
Standard 
Deviation 
95% Confidence 
Interval for Mean 
  
Lower 
Bound 
Upper 
Bound 
DICE 
Target 63 0.80 0.08 0.78 0.82 
Serial 
Organs 126 0.73 0.12 0.71 0.76 
Parallel 
Organs 99 0.74 0.09 0.72 0.76 
 
Total 288 0.75 0.11 0.74 0.76 
JACCARD 
Target 63 0.67 0.10 0.64 0.69 
Serial 
Organs 126 0.59 0.13 0.57 0.62 
Parallel 
Organs 99 0.59 0.11 0.57 0.61 
 
Total 288 0.61 0.12 0.60 0.62 
RIET 
Target 63 0.65 0.10 0.62 0.67 
Serial 
Organs 126 0.57 0.13 0.54 0.59 
Parallel 
Organs 99 0.56 0.12 0.54 0.59 
 
Total 288 0.58 0.13 0.57 0.60 
1-GMI 
Target 63 0.78 0.13 0.74 0.81 
Serial 
Organs 126 0.77 0.16 0.74 0.80 
Parallel 
Organs 99 0.71 0.12 0.69 0.74 
 
Total 288 0.75 0.14 0.74 0.77 
Table 3: Summary of descriptive statistics for the DICE, JACCARD, RIET and 1-GMI for OAR-P (parotid glands), 
OAR-S (spinal cord and brainstem) and TARGET (high dose CTV1)  
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Figure 8: A boxplot displaying the distribution of the DICE, JACCARD, RIET and 1-GMI for OAR-P (parotid 
glands), OAR-S (spinal cord and brainstem) and TARGET (high dose CTV1) 
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A pairwise comparison with Bonferroni correction was performed on each of the 
groups for each conformity indice (DICE, JACCARD, RIET and 1-GMI). The analysis 
revealed the following statistical differences between each group and indice 
analysed: 
 
DICE 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
No significant difference was found between OAR-S and OAR-P (p=1.00) 
 
JACCARD 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
No significant difference was found between OAR-S and OAR-P (p=1.00) 
 
RIET 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
No significant difference was found between OAR-S and OAR-P (p=1.00) 
 
1-GMI 
 
No significant difference was found between Target and OAR-S (p=1.00) 
A significant difference was found between Target and OAR-P (p<0.05) 
A significant difference was found between OAR-S and OAR-P (p<0.05) 
 
To summarise, a statistically significant difference was detected for the DICE, 
JACCARD and RIET indices when the target volume contours (TARGET) were 
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compared with both the serial and parallel organ at risk contours (OAR-S and OAR-
P). 
There was no statistical difference for the DICE, JACCARD and RIET indices when the 
serial and parallel organ at risk contours were compared with each other (OAR-S 
and OAR-P). 
For the 1-GMI indice, there was no statistically significant difference between the 
target contours (TARGET) and serial organ at risk contours (OAR-S). There was a 
statistically significant difference between the target contours (TARGET) and 
parallel organ at risk contours (OAR-P). Finally, there was also a statistically 
significant difference between the serial and parallel organ at risk contours (OAR-S 
and OAR-P). 
The local conformity index (L-CI) data maps for each of the structures contained 
within each group can also be seen in Figure 9 – Figure 12. An explanation of how 
the data was created and should be interpreted can be found in Appendix 1. The 
DICE, JACCARD, RIET and 1-GMI indices are single metrics of conformity and 
therefore condense and obscure the over, under and sometimes subtle differences 
that exist between clinician contours. The L-CI data maps on the other hand help to 
maintain this level of detail and permit a visual interpretation of it. The L-CI data 
maps for the ART-DECO and COSTAR target volume and OAR structures 
demonstrate where the highest and lowest levels of conformity exist and clearly 
reveal those areas of over and under outlining within each submitted target and 
OAR structure. The value of L-CI will be discussed in more detail in the resubmission 
data analysis section of Chapter 6: Discussion. 
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Figure 9: L-CI Map for ART-DECO Pre-Trial Benchmark Case 2 CTV1 (No Conformity i.e. contour not present (L-
CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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Figure 10: L-CI Map for COSTAR Pre-Trial Benchmark Case 1 Spinal Cord (No Conformity i.e. contour not 
present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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Figure 11: L-CI Map for ART-DECO Pre-Trial Benchmark Case 2 Brainstem (No Conformity i.e. contour not 
present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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Figure 12: L-CI Map for ART-DECO Pre-Trial Benchmark Case 1 Left Parotid (No Conformity i.e. contour not 
present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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Chapter 4: Results of Inter-Observer Variation Analysis Between Target 
Volume, Serial and Parallel OAR Outlines Within Two Lung Cancer Clinical 
Trials 
 
I collected all the pre-trial benchmark cases for the IDEAL and i-START trials up until 
November 2012 in DICOM format. In total 198 structures were analysed from both 
trials based upon three distinct groups – target structures (which included the CTV); 
serial organs at risk which (included spinal cord and oesophagus) and parallel 
organs at risk (which included the heart and lungs). The number of structures 
analysed within each group varied because some submitting clinicians did not 
include outlines for some of the organs at risk. Details of these grouping are 
summarised in Table 4 below.  
 
Group Name 
Structures 
Included in 
Group 
Number of 
Structures 
Analysed 
Total 
Target 
Structures 
CTV1 40 40 
Serial 
Organs 
Spinal Cord 32 
68 
Oesophagus 36 
Parallel 
Organs 
Heart 36 
90 
Lungs 54 
Table 4: Summary of IDEAL and i-START Target and OAR Contour Groupings 
 
Descriptive statistics are summarised for the DICE, JACCARD, RIET and 1-GMI 
indices for each respective group in Table 5. The boxplot as shown in Figure 13 
demonstrates that the parallel organs (heart and lungs) had the highest levels of 
conformality, followed by the target contour (CTV1) and finally the serial organs at 
risk (oesophagus and spinal cord).  
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Number 
of 
contours 
Mean 
Index 
Value 
Standard 
Deviation 
95% Confidence 
Interval for Mean 
  
Lower 
Bound 
Upper 
Bound 
DICE 
Target 40 0.84 0.10 0.81 0.87 
Serial 
Organs 
68 0.69 0.13 0.65 0.72 
Parallel 
Organs 
90 0.95 0.03 0.95 0.96 
 
Total 198 0.84 0.15 0.82 0.86 
JACCARD 
Target 40 0.73 0.13 0.69 0.77 
Serial 
Organs 
68 0.54 0.15 0.50 0.57 
Parallel 
Organs 
90 0.91 0.06 0.90 0.92 
 
Total 198 0.75 0.20 0.72 0.77 
RIET 
Target 40 0.72 0.14 0.68 0.77 
Serial 
Organs 
68 0.50 0.16 0.47 0.54 
Parallel 
Organs 
90 0.91 0.06 0.90 0.92 
 
Total 198 0.73 0.22 0.70 0.76 
1-GMI 
Target 40 0.86 0.12 0.82 0.90 
Serial 
Organs 
68 0.74 0.19 0.70 0.79 
Parallel 
Organs 
90 0.94 0.05 0.93 0.95 
 
Total 198 0.86 0.16 0.84 0.88 
Table 5: Summary of descriptive statistics for the DICE, JACCARD, RIET and 1-GMI for Target (CTV), Serial 
Organs (spinal cord and oesophagus) and Parallel Organs (heart and lungs).  
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Figure 13: A boxplot displaying the distribution of the DICE, JACCARD, RIET and 1-GMI for OAR-P (heart and 
lungs), OAR-S (spinal cord and oesophagus) and TARGET (CTV) 
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A pairwise comparison with Bonferroni correction was performed on each of the 
groups for each conformity indice (DICE, JACCARD, RIET and 1-GMI). The analysis 
revealed the following statistical differences between each group and indice 
analysed: 
 
DICE 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
A significant difference was found between OAR-S and OAR-P (p<0.05) 
 
JACCARD 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
A significant difference was found between OAR-S and OAR-P (p<0.05) 
 
RIET 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
A significant difference was found between OAR-S and OAR-P (p<0.05) 
 
1-GMI 
 
A significant difference was found between Target and OAR-S (p<0.05) 
A significant difference was found between Target and OAR-P (p<0.05) 
A significant difference was found between OAR-S and OAR-P (p<0.05) 
 
To summarise, a statistically significant difference was detected for the DICE, 
JACCARD, RIET and 1-GMI indices when target volume contours (TARGET) were 
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compared with either the serial or parallel organ at risk contours (OAR-S and OAR-
P). 
A statistically significant difference was also detected for DICE, JACCARD, RIET and 
1-GMI indices when the serial and parallel organ at risk contours were compared 
with each other (OAR-S and OAR-P). 
In terms of the individual structures themselves, the boxplot as shown in Figure 14 
demonstrates that the lung contours had the highest level of conformity, followed 
by heart, CTV, spinal cord and oesophagus respectively. Table 6 below summarises 
the rankings of the organs at risk. 
 
Rank Structure Name Group 
1st Lung OAR-P 
2nd Heart OAR-P 
3rd CTV1 Target Structure Group 
4th Spinal Cord OAR-S 
5th Oesophagus OAR-S 
Table 6: Structure and Groups Rankings Based on Conformality Analysis of the IDEAL and i-START Lung Cancer 
Trials 
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Figure 14: A boxplot displaying the distribution of the DICE, JACCARD, RIET and 1-GMI for individual 
structures analysed (heart, lung, oesophagus, spinal cord and CTV) 
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Example L-CI data maps for each of the structures contained within each group 
analysed can also be seen in Figure 15 – Figure 19. As mentioned in Chapter 3: 
Results of Inter-Observer Variation Analysis Between Target Volume, Serial and 
Parallel OAR Outlines Within Two Head and Neck Clinical Trials, the DICE, JACCARD, 
RIET and 1-GMI indices are single metrics of conformity and therefore condense 
and obscure the over, under and sometimes subtle differences that can exist 
between clinician contours. The L-CI data maps for the IDEAL and i-START target 
volume and OAR structures demonstrate where the highest and lowest levels of 
conformity exist and clearly reveal those areas of over and under outlining within 
each submitted target and OAR structure. The L-CI data map allows immediate 
recognition of where issues may lie and helps to direct the RTQA review to areas in 
need of greater scrutiny to try and explain why the conformality value seen is lower 
than expected e.g. misinterpretation of normal CT anatomy or misunderstanding of 
the radiotherapy contouring protocol. 
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Figure 15: L-CI Map for IDEAL Pre-Trial Benchmark Case 2 CTV1 (No Conformity i.e. contour not present (L-CI = 
0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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Figure 16:  L-CI Map for IDEAL Pre-Trial Benchmark Case 2 Spinal Cord (No Conformity i.e. contour not present 
(L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
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31 -10.20 0.77 0.66 0.81 0.76 0.80 0.83 0.47 0.75 0.81 0.84 0.88 1.00
32 -9.90 0.74 0.67 0.86 0.76 0.78 0.88 0.55 0.70 0.83 0.85 0.89 1.00
33 -9.60 0.79 0.70 0.82 0.88 0.85 0.88 0.35 0.75 0.87 0.87 0.75 1.00
34 -9.30 0.83 0.75 0.82 0.88 0.85 0.89 0.39 0.71 0.85 0.87 0.79 1.00
35 -9.00 0.85 0.76 0.76 0.91 0.81 0.91 0.39 0.74 0.79 0.87 0.81 1.00
36 -8.70 0.74 0.77 0.79 0.86 0.85 0.79 0.36 0.75 0.77 0.83 0.75 1.00
37 -8.40 0.74 0.70 0.85 0.78 0.85 0.85 0.40 0.74 0.75 0.86 0.77 1.00
38 -8.10 0.72 0.70 0.71 0.72 0.69 0.84 0.46 0.76 0.70 0.86 0.81 1.00
39 -7.80 0.75 0.75 0.82 0.72 0.79 0.86 0.37 0.80 0.73 0.82 0.86 1.00
40 -7.50 0.74 0.84 0.75 0.73 0.85 0.84 0.38 0.76 0.75 0.71 0.82 1.00
41 -7.20 0.74 0.80 0.82 0.84 0.82 0.80 0.40 0.78 0.75 0.67 0.88 1.00
42 -6.90 0.79 0.78 0.88 0.86 0.91 0.83 0.33 0.75 0.68 0.79 0.89 1.00
43 -6.60 0.82 0.71 0.73 0.85 0.85 0.81 0.29 0.71 0.68 0.81 0.88 1.00
44 -6.30 0.81 0.71 0.74 0.83 0.79 0.87 0.31 0.74 0.78 0.68 0.91 1.00
45 -6.00 0.83 0.78 0.84 0.76 0.80 0.88 0.44 0.78 0.71 0.82 0.84 1.00
46 -5.70 0.84 0.86 0.77 0.68 0.81 0.87 0.46 0.78 0.76 0.83 0.85 1.00
47 -5.40 0.83 0.84 0.81 0.72 0.90 0.88 0.43 0.84 0.82 0.85 0.77 1.00
48 -5.10 0.89 0.86 0.76 0.74 0.88 0.90 0.48 0.84 0.82 0.81 0.78 1.00
49 -4.80 0.90 0.83 0.89 0.76 0.89 0.88 0.33 0.83 0.89 0.83 0.76 1.00
50 -4.50 0.87 0.71 0.83 0.88 0.83 0.89 0.35 0.74 0.88 0.78 0.75 1.00
51 -4.20 0.86 0.65 0.74 0.85 0.83 0.88 0.33 0.64 0.85 0.72 0.77 1.00
52 -3.90 0.91 0.71 0.83 0.93 0.89 0.92 0.27 0.72 0.83 0.86 0.82 1.00
53 -3.60 0.88 0.89 0.76 0.94 0.89 0.87 0.33 0.81 0.82 0.89 0.83 1.00
54 -3.30 0.86 0.89 0.81 0.80 0.88 0.87 0.45 0.82 0.79 0.86 0.81 1.00
55 -3.00 0.84 0.80 0.78 0.77 0.83 0.88 0.49 0.82 0.76 0.85 0.80 1.00
56 -2.70 0.80 0.73 0.78 0.70 0.85 0.85 0.48 0.79 0.77 0.84 0.83 1.00
57 -2.40 0.81 0.70 0.82 0.77 0.88 0.89 0.39 0.79 0.84 0.80 0.81 1.00
58 -2.10 0.84 0.69 0.79 0.83 0.87 0.86 0.37 0.77 0.85 0.84 0.83 1.00
59 -1.80 0.84 0.69 0.74 0.89 0.87 0.86 0.39 0.75 0.88 0.84 0.81 1.00
60 -1.50 0.87 0.70 0.69 0.81 0.89 0.92 0.37 0.71 0.87 0.82 0.83 1.00
61 -1.20 0.84 0.76 0.66 0.86 0.91 0.90 0.31 0.64 0.86 0.81 0.82 1.00
62 -0.90 0.82 0.71 0.69 0.92 0.88 0.87 0.37 0.70 0.86 0.80 0.79 1.00
63 -0.60 0.81 0.75 0.80 0.82 0.87 0.85 0.43 0.82 0.82 0.88 0.81 1.00
64 -0.30 0.78 0.74 0.85 0.75 0.84 0.83 0.42 0.83 0.82 0.88 0.79 1.00
65 0.00 0.78 0.62 0.74 0.75 0.81 0.76 0.40 0.78 0.77 0.79 0.78 1.00
66 0.30 0.83 0.51 0.72 0.67 0.87 0.85 0.30 0.77 0.79 0.80 0.65 1.00
67 0.60 0.87 0.65 0.66 0.73 0.92 0.86 0.27 0.67 0.82 0.81 0.65 1.00
68 0.90 0.89 0.72 0.76 0.85 0.90 0.88 0.37 0.73 0.82 0.86 0.84 1.00
69 1.20 0.86 0.71 0.83 0.85 0.94 0.85 0.37 0.71 0.83 0.89 0.84 1.00
70 1.50 0.83 0.60 0.80 0.83 0.89 0.83 0.38 0.71 0.78 0.89 0.79 1.00
71 1.80 0.76 0.71 0.64 0.89 0.82 0.79 0.40 0.78 0.75 0.84 0.78 1.00
72 2.10 0.72 0.73 0.80 0.87 0.81 0.79 0.38 0.84 0.73 0.92 0.76 1.00
73 2.40 0.69 0.68 0.74 0.76 0.79 0.77 0.45 0.80 0.67 0.85 0.77 1.00
74 2.70 0.65 0.48 0.65 0.69 0.72 0.73 0.37 0.75 0.68 0.83 0.64 1.00
75 3.00 0.68 0.39 0.61 0.79 0.74 0.79 0.30 0.73 0.71 0.73 0.67 1.00
76 3.30 0.69 0.39 0.69 0.76 0.73 0.78 0.26 0.77 0.68 0.72 0.66 1.00
77 3.60 0.80 0.33 0.82 0.83 0.80 0.81 0.30 0.63 0.86 0.72 0.81 1.00
78 3.90 0.81 0.71 0.79 0.81 0.85 0.87 0.31 0.63 0.88 0.84 0.81 1.00
79 4.20 0.83 0.73 0.67 0.78 0.89 0.88 0.25 0.68 0.84 0.83 0.83 1.00
80 4.50 0.86 0.73 0.76 0.92 0.92 0.87 0.34 0.71 0.79 0.86 0.87 1.00
81 4.80 0.85 0.65 0.83 0.90 0.88 0.90 0.35 0.79 0.77 0.84 0.88 1.00
82 5.10 0.85 0.87 0.77 0.80 0.84 0.89 0.40 0.81 0.74 0.00 0.93 1.00
83 5.40 0.81 0.79 0.88 0.75 0.80 0.86 0.42 0.76 0.71 0.00 0.84 1.00
84 5.70 0.75 0.77 0.80 0.78 0.83 0.83 0.25 0.75 0.79 0.00 0.76 1.00
85 6.00 0.83 0.78 0.83 0.69 0.74 0.96 0.36 0.74 0.69 0.00 0.76 1.00
86 6.30 0.86 0.79 0.80 0.74 0.84 0.90 0.34 0.65 0.70 0.00 0.77 1.00
87 6.60 0.83 0.60 0.65 0.85 0.85 0.91 0.39 0.78 0.76 0.00 0.73 1.00
88 6.90 0.86 0.77 0.75 0.87 0.87 0.91 0.38 0.79 0.84 0.00 0.88 1.00
89 7.20 0.82 0.81 0.81 0.96 0.82 0.89 0.37 0.81 0.83 0.00 0.86 1.00
90 7.50 0.81 0.85 0.80 0.91 0.88 0.85 0.33 0.83 0.83 0.00 0.78 1.00
91 7.80 0.76 0.61 0.75 0.83 0.86 0.77 0.44 0.74 0.84 0.00 0.69 1.00
92 8.10 0.71 0.73 0.72 0.94 0.82 0.73 0.32 0.83 0.85 0.00 0.66 1.00
93 8.40 0.76 0.68 0.73 0.83 0.85 0.77 0.32 0.77 0.00 0.00 0.68 1.00
94 8.70 0.78 0.62 0.72 0.77 0.78 0.83 0.33 0.81 0.00 0.00 0.69 1.00
95 9.00 0.79 0.61 0.74 0.00 0.76 0.84 0.44 0.78 0.00 0.00 0.73 1.00
96 9.30 0.80 0.62 0.68 0.00 0.77 0.86 0.39 0.74 0.00 0.00 0.73 1.00
97 9.60 0.85 0.54 0.65 0.00 0.76 0.86 0.38 0.74 0.00 0.00 0.71 1.00
98 9.90 0.86 0.56 0.88 0.00 0.77 0.84 0.36 0.71 0.00 0.00 0.79 1.00
99 10.20 0.00 0.60 0.84 0.00 0.79 0.84 0.00 0.79 0.00 0.00 0.76 1.00
100 10.50 0.00 0.58 0.89 0.00 0.78 0.81 0.00 0.77 0.00 0.00 0.76 1.00
101 10.80 0.00 0.76 0.89 0.00 0.84 0.80 0.00 0.81 0.00 0.00 0.83 1.00
102 11.10 0.00 0.00 0.00 0.00 0.00 0.00
103 11.40 0.00 0.00 0.00 0.00 0.00 0.00
104 11.70 0.00 0.00 0.00 0.00
105 12.00 0.00 0.00 0.00 0.00
9 10 11 124 5 6 7 81 2 3
CT Slice No. Z
PI No.
Gold 
Standard
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Figure 17:  L-CI Map for IDEAL Pre-Trial Benchmark Case 1 Oesophagus (No Conformity i.e. contour not 
present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
 
  
L-CI Map For IDEAL Pre-Trial Benchmark Case 1 Oesophagus
1 -13.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
2 -13.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
3 -13.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
4 -12.90 0.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
5 -12.60 0.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
6 -12.30 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
7 -12.00 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
8 -11.70 0.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.46 1.00
9 -11.40 0.56 0.00 0.00 0.00 0.00 0.00 0.81 0.00 0.00 0.00 0.00 0.70 1.00
10 -11.10 0.69 0.00 0.00 0.00 0.00 0.00 0.86 0.00 0.00 0.00 0.00 0.81 1.00
11 -10.80 0.72 0.86 0.00 0.00 0.00 0.00 0.89 0.00 0.00 0.00 0.00 0.81 1.00
12 -10.50 0.66 0.83 0.00 0.00 0.00 0.00 0.84 0.00 0.00 0.77 0.00 0.88 1.00
13 -10.20 0.70 0.82 0.00 0.00 0.00 0.00 0.85 0.00 0.69 0.77 0.00 0.88 1.00
14 -9.90 0.71 0.78 0.00 0.00 0.00 0.00 0.77 0.00 0.61 0.71 0.00 0.74 1.00
15 -9.60 0.70 0.81 0.00 0.00 0.00 0.00 0.82 0.00 0.54 0.65 0.00 0.78 1.00
16 -9.30 0.66 0.79 0.00 0.00 0.00 0.00 0.86 0.00 0.63 0.70 0.00 0.79 1.00
17 -9.00 0.66 0.85 0.00 0.00 0.00 0.00 0.80 0.00 0.61 0.67 0.00 0.88 1.00
18 -8.70 0.63 0.83 0.15 0.00 0.00 0.67 0.83 0.44 0.66 0.72 0.00 0.87 1.00
19 -8.40 0.57 0.88 0.15 0.00 0.00 0.68 0.88 0.53 0.52 0.69 0.00 0.89 1.00
20 -8.10 0.68 0.86 0.16 0.00 0.00 0.63 0.77 0.48 0.67 0.79 0.00 0.78 1.00
21 -7.80 0.70 0.78 0.17 0.00 0.00 0.63 0.82 0.66 0.78 0.79 0.00 0.79 1.00
22 -7.50 0.85 0.83 0.16 0.00 0.00 0.74 0.84 0.68 0.67 0.87 0.00 0.86 1.00
23 -7.20 0.76 0.72 0.18 0.00 0.00 0.70 0.82 0.57 0.75 0.79 0.00 0.72 1.00
24 -6.90 0.77 0.82 0.27 0.00 0.00 0.70 0.73 0.57 0.76 0.79 0.00 0.78 1.00
25 -6.60 0.78 0.82 0.45 0.00 0.00 0.82 0.70 0.44 0.75 0.79 0.00 0.84 1.00
26 -6.30 0.74 0.80 0.50 0.00 0.00 0.63 0.69 0.45 0.59 0.78 0.00 0.76 1.00
27 -6.00 0.71 0.71 0.54 0.00 0.00 0.55 0.77 0.49 0.68 0.68 0.00 0.81 1.00
28 -5.70 0.71 0.72 0.48 0.78 0.78 0.58 0.69 0.34 0.59 0.72 0.00 0.65 1.00
29 -5.40 0.73 0.78 0.48 0.79 0.79 0.65 0.75 0.42 0.71 0.77 0.00 0.85 1.00
30 -5.10 0.70 0.78 0.36 0.77 0.77 0.58 0.67 0.57 0.67 0.72 0.72 0.77 1.00
31 -4.80 0.74 0.79 0.46 0.75 0.75 0.76 0.77 0.43 0.71 0.74 0.73 0.82 1.00
32 -4.50 0.68 0.78 0.58 0.73 0.73 0.72 0.86 0.62 0.76 0.80 0.84 0.85 1.00
33 -4.20 0.70 0.78 0.57 0.69 0.69 0.67 0.79 0.52 0.80 0.75 0.79 0.87 1.00
34 -3.90 0.77 0.76 0.58 0.76 0.76 0.69 0.73 0.59 0.75 0.76 0.83 0.80 1.00
35 -3.60 0.69 0.81 0.61 0.87 0.87 0.68 0.78 0.48 0.74 0.77 0.84 0.89 1.00
36 -3.30 0.54 0.85 0.58 0.73 0.73 0.78 0.84 0.69 0.77 0.92 0.76 0.67 1.00
37 -3.00 0.60 0.82 0.63 0.67 0.67 0.72 0.85 0.58 0.81 0.87 0.88 0.81 1.00
38 -2.70 0.68 0.79 0.71 0.68 0.68 0.71 0.78 0.60 0.75 0.77 0.83 0.83 1.00
39 -2.40 0.83 0.88 0.58 0.73 0.73 0.69 0.86 0.64 0.63 0.76 0.72 0.84 1.00
40 -2.10 0.79 0.74 0.64 0.71 0.71 0.77 0.88 0.66 0.56 0.82 0.81 0.86 1.00
41 -1.80 0.82 0.73 0.68 0.73 0.73 0.62 0.87 0.74 0.68 0.78 0.82 0.84 1.00
42 -1.50 0.81 0.68 0.67 0.74 0.74 0.82 0.81 0.81 0.78 0.76 0.79 0.85 1.00
43 -1.20 0.75 0.66 0.59 0.59 0.59 0.85 0.90 0.89 0.86 0.82 0.74 0.82 1.00
44 -0.90 0.60 0.59 0.60 0.78 0.78 0.74 0.85 0.69 0.80 0.82 0.71 0.84 1.00
45 -0.60 0.54 0.65 0.38 0.76 0.76 0.71 0.82 0.58 0.76 0.82 0.72 0.79 1.00
46 -0.30 0.40 0.57 0.18 0.63 0.63 0.88 0.80 0.74 0.64 0.75 0.72 0.71 1.00
47 0.00 0.33 0.40 0.06 0.40 0.40 0.46 0.64 0.23 0.42 0.52 0.64 0.21 1.00
48 0.30 0.35 0.54 0.29 0.30 0.30 0.50 0.74 0.49 0.51 0.56 0.70 0.39 1.00
49 0.60 0.61 0.76 0.47 0.44 0.44 0.66 0.65 0.42 0.82 0.63 0.66 0.78 1.00
50 0.90 0.65 0.70 0.64 0.52 0.52 0.75 0.75 0.57 0.75 0.69 0.79 0.77 1.00
51 1.20 0.64 0.70 0.51 0.49 0.49 0.74 0.80 0.46 0.77 0.75 0.73 0.76 1.00
52 1.50 0.71 0.57 0.58 0.59 0.59 0.77 0.74 0.48 0.62 0.57 0.60 0.70 1.00
53 1.80 0.68 0.57 0.56 0.60 0.60 0.69 0.72 0.37 0.54 0.50 0.54 0.75 1.00
54 2.10 0.68 0.55 0.46 0.51 0.51 0.59 0.73 0.44 0.53 0.64 0.67 0.68 1.00
55 2.40 0.75 0.57 0.44 0.47 0.47 0.66 0.65 0.40 0.53 0.73 0.54 0.89 1.00
56 2.70 0.71 0.51 0.34 0.41 0.41 0.75 0.64 0.47 0.56 0.76 0.55 0.78 1.00
57 3.00 0.63 0.45 0.15 0.38 0.38 0.80 0.70 0.61 0.50 0.77 0.43 0.78 1.00
58 3.30 0.73 0.50 0.28 0.49 0.49 0.71 0.71 0.64 0.51 0.73 0.08 0.70 1.00
59 3.60 0.80 0.46 0.38 0.50 0.50 0.66 0.68 0.86 0.53 0.64 0.38 0.73 1.00
60 3.90 0.73 0.51 0.54 0.45 0.45 0.68 0.63 0.64 0.53 0.54 0.65 0.81 1.00
61 4.20 0.64 0.58 0.57 0.39 0.39 0.69 0.51 0.66 0.51 0.46 0.46 0.71 1.00
62 4.50 0.61 0.63 0.69 0.46 0.46 0.70 0.59 0.56 0.63 0.59 0.63 0.67 1.00
63 4.80 0.48 0.64 0.44 0.65 0.65 0.72 0.68 0.58 0.54 0.58 0.54 0.63 1.00
64 5.10 0.61 0.49 0.35 0.49 0.49 0.29 0.52 0.46 0.40 0.44 0.48 0.67 1.00
65 5.40 0.67 0.67 0.49 0.59 0.59 0.70 0.71 0.80 0.60 0.64 0.68 0.71 1.00
66 5.70 0.54 0.67 0.51 0.50 0.50 0.68 0.68 0.62 0.64 0.70 0.83 0.62 1.00
67 6.00 0.51 0.68 0.48 0.44 0.44 0.60 0.63 0.79 0.51 0.68 0.74 0.74 1.00
68 6.30 0.70 0.70 0.54 0.57 0.57 0.80 0.89 0.75 0.56 0.87 0.72 0.79 1.00
69 6.60 0.76 0.68 0.62 0.53 0.53 0.70 0.83 0.65 0.57 0.72 0.76 0.67 1.00
70 6.90 0.69 0.68 0.71 0.48 0.48 0.80 0.77 0.77 0.66 0.73 0.80 0.78 1.00
71 7.20 0.71 0.77 0.63 0.50 0.50 0.75 0.85 0.69 0.67 0.76 0.80 0.80 1.00
72 7.50 0.74 0.71 0.64 0.56 0.56 0.66 0.76 0.62 0.57 0.68 0.71 0.67 1.00
73 7.80 0.81 0.77 0.53 0.63 0.63 0.45 0.74 0.63 0.51 0.59 0.24 0.63 1.00
74 8.10 0.85 0.82 0.54 0.61 0.61 0.61 0.78 0.57 0.57 0.66 0.42 0.64 1.00
75 8.40 0.69 0.72 0.47 0.66 0.66 0.59 0.85 0.49 0.54 0.47 0.31 0.72 1.00
76 8.70 0.70 0.73 0.44 0.70 0.70 0.64 0.83 0.50 0.58 0.47 0.20 0.59 1.00
77 9.00 0.68 0.81 0.53 0.63 0.63 0.81 0.84 0.59 0.64 0.41 0.40 0.65 1.00
78 9.30 0.71 0.83 0.58 0.83 0.83 0.54 0.79 0.71 0.53 0.56 0.43 0.73 1.00
79 9.60 0.65 0.75 0.70 0.81 0.81 0.71 0.87 0.79 0.56 0.74 0.58 0.78 1.00
80 9.90 0.66 0.71 0.72 0.72 0.72 0.71 0.84 0.66 0.59 0.68 0.28 0.63 1.00
81 10.20 0.76 0.79 0.61 0.84 0.84 0.78 0.81 0.45 0.55 0.61 0.48 0.68 1.00
82 10.50 0.71 0.80 0.60 0.80 0.80 0.69 0.82 0.54 0.52 0.59 0.45 0.67 1.00
83 10.80 0.61 0.77 0.54 0.63 0.63 0.77 0.76 0.59 0.46 0.57 0.41 0.79 1.00
84 11.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
85 11.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
86 11.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
87 12.00 0.00 0.00 0.00 0.00 0.00 0.00
88 12.30 0.00 0.00 0.00 0.00
89 12.60 0.00 0.00
90 12.90
11 126 7 8 9 10
ZCT Slice No.
PI No.
Gold 
Standard1 2 3 4 5
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Figure 18: L-CI Map for IDEAL Pre-Trial Benchmark Case 1 Heart (No Conformity i.e. contour not present (L-CI 
= 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00)) 
 
 
  
L-CI Map For IDEAL Pre-Trial Benchmark Case 1 Heart
1 -13.80
2 -13.50
3 -13.20
4 -12.90
5 -12.60
6 -12.30
7 -12.00
8 -11.70
9 -11.40
10 -11.10
11 -10.80
12 -10.50
13 -10.20
14 -9.90
15 -9.60
16 -9.30
17 -9.00
18 -8.70
19 -8.40
20 -8.10
21 -7.80
22 -7.50
23 -7.20
24 -6.90
25 -6.60
26 -6.30
27 -6.00
28 -5.70
29 -5.40
30 -5.10
31 -4.80
32 -4.50
33 -4.20
34 -3.90
35 -3.60
36 -3.30
37 -3.00
38 -2.70
39 -2.40
40 -2.10
41 -1.80
42 -1.50
43 -1.20
44 -0.90
45 -0.60
46 -0.30 0.00
47 0.00 0.00
48 0.30 0.00
49 0.60 0.00
50 0.90 0.00
51 1.20 0.00
52 1.50 0.00
53 1.80 0.00
54 2.10 0.00
55 2.40 0.00 0.00 0.00 0.00
56 2.70 0.80 0.87 0.80 0.00 0.00 0.91 0.00 0.88 0.91 0.00 0.00 0.95 1.00
57 3.00 0.81 0.89 0.81 0.86 0.86 0.95 0.92 0.90 0.93 0.00 0.00 0.94 1.00
58 3.30 0.87 0.92 0.89 0.90 0.90 0.93 0.93 0.90 0.95 0.00 0.88 0.94 1.00
59 3.60 0.86 0.88 0.92 0.93 0.93 0.94 0.94 0.92 0.94 0.00 0.89 0.94 1.00
60 3.90 0.87 0.87 0.93 0.91 0.91 0.94 0.93 0.90 0.95 0.00 0.88 0.93 1.00
61 4.20 0.93 0.90 0.91 0.88 0.88 0.95 0.95 0.90 0.95 0.00 0.90 0.92 1.00
62 4.50 0.92 0.83 0.93 0.93 0.93 0.95 0.93 0.88 0.92 0.00 0.91 0.90 1.00
63 4.80 0.91 0.89 0.91 0.89 0.89 0.92 0.94 0.90 0.94 0.00 0.90 0.89 1.00
64 5.10 0.89 0.88 0.93 0.91 0.91 0.96 0.93 0.92 0.92 0.95 0.92 0.89 1.00
65 5.40 0.88 0.87 0.94 0.90 0.90 0.95 0.94 0.92 0.92 0.94 0.93 0.89 1.00
66 5.70 0.88 0.88 0.94 0.91 0.91 0.95 0.93 0.92 0.95 0.94 0.95 0.94 1.00
67 6.00 0.90 0.88 0.95 0.93 0.93 0.96 0.95 0.94 0.96 0.94 0.95 0.95 1.00
68 6.30 0.88 0.88 0.96 0.94 0.94 0.97 0.94 0.93 0.94 0.94 0.94 0.95 1.00
69 6.60 0.84 0.86 0.95 0.90 0.90 0.94 0.92 0.91 0.90 0.94 0.91 0.93 1.00
70 6.90 0.86 0.87 0.94 0.95 0.95 0.96 0.94 0.92 0.91 0.95 0.91 0.94 1.00
71 7.20 0.87 0.86 0.94 0.93 0.93 0.95 0.94 0.89 0.90 0.94 0.91 0.93 1.00
72 7.50 0.90 0.88 0.94 0.94 0.94 0.95 0.93 0.94 0.92 0.94 0.92 0.95 1.00
73 7.80 0.93 0.92 0.92 0.96 0.96 0.96 0.95 0.92 0.94 0.94 0.91 0.96 1.00
74 8.10 0.92 0.93 0.92 0.95 0.95 0.97 0.94 0.94 0.94 0.94 0.92 0.97 1.00
75 8.40 0.92 0.93 0.93 0.94 0.94 0.96 0.95 0.92 0.96 0.94 0.94 0.96 1.00
76 8.70 0.92 0.92 0.94 0.97 0.97 0.96 0.93 0.90 0.96 0.93 0.93 0.96 1.00
77 9.00 0.92 0.91 0.93 0.95 0.95 0.96 0.91 0.88 0.96 0.94 0.94 0.97 1.00
78 9.30 0.92 0.92 0.90 0.94 0.94 0.96 0.92 0.91 0.97 0.94 0.94 0.98 1.00
79 9.60 0.91 0.93 0.94 0.95 0.95 0.97 0.92 0.88 0.96 0.95 0.95 0.96 1.00
80 9.90 0.93 0.95 0.94 0.94 0.94 0.96 0.93 0.87 0.94 0.95 0.96 0.93 1.00
81 10.20 0.92 0.94 0.91 0.93 0.93 0.94 0.94 0.83 0.93 0.93 0.93 0.91 1.00
82 10.50 0.93 0.92 0.89 0.91 0.91 0.91 0.92 0.86 0.93 0.91 0.92 0.91 1.00
83 10.80 0.91 0.90 0.87 0.89 0.89 0.92 0.91 0.88 0.82 0.91 0.90 0.95 1.00
84 11.10 0.92 0.90 0.84 0.87 0.87 0.94 0.92 0.87 0.84 0.90 0.88 0.92 1.00
85 11.40 0.89 0.90 0.89 0.89 0.89 0.91 0.94 0.79 0.75 0.87 0.89 0.90 1.00
86 11.70 0.90 0.91 0.92 0.94 0.94 0.91 0.92 0.82 0.61 0.85 0.92 0.93 1.00
87 12.00 0.89 0.88 0.89 0.83 0.83 0.87 0.90 0.85 0.60 0.80 0.85 0.92 1.00
88 12.30 0.91 0.89 0.90 0.77 0.77 0.86 0.88 0.62 0.61 0.71 0.82 0.91 1.00
89 12.60 0.86 0.71 0.77 0.80 0.80 0.79 0.85 0.50 0.69 0.81 0.63 0.89 1.00
90 12.90 0.64 0.77 0.00 0.53 0.53 0.77 0.85 0.00 0.26 0.51 0.67 0.52 1.00
9 10 11 124 5 6 7 81 2 3
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Figure 19: L-CI Map for i-START Pre-Trial Benchmark Case 1 Left Lung (No Conformity i.e. contour not present 
(L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00))  
L-CI Map For i-START Pre-Trial Benchmark Case 1 Left Lung
1 -13.80
2 -13.50
3 -13.20
4 -12.90
5 -12.60
6 -12.30
7 -12.00
8 -11.70
9 -11.40
10 -11.10
11 -10.80
12 -10.50
13 -10.20
14 -9.90
15 -9.60
16 -9.30
17 -9.00
18 -8.70 0.72 0.86 1.00 0.59 1.00
19 -8.40 0.82 0.95 1.00 0.81 1.00
20 -8.10 0.90 0.94 1.00 0.89 1.00
21 -7.80 0.85 0.95 1.00 0.91 1.00
22 -7.50 0.91 0.96 1.00 0.90 1.00
23 -7.20 0.94 0.96 1.00 0.94 1.00
24 -6.90 0.91 0.97 1.00 0.94 1.00
25 -6.60 0.96 0.97 1.00 0.95 1.00
26 -6.30 0.96 0.97 0.99 0.95 1.00
27 -6.00 0.97 0.97 0.99 0.95 1.00
28 -5.70 0.95 0.97 1.00 0.96 1.00
29 -5.40 0.98 0.97 1.00 0.95 1.00
30 -5.10 0.98 0.98 1.00 0.96 1.00
31 -4.80 0.96 0.97 0.99 0.95 1.00
32 -4.50 0.97 0.97 0.99 0.96 1.00
33 -4.20 0.97 0.97 0.99 0.96 1.00
34 -3.90 0.96 0.97 0.99 0.97 1.00
35 -3.60 0.93 0.98 1.00 0.97 1.00
36 -3.30 0.96 0.97 0.99 0.97 1.00
37 -3.00 0.96 0.97 0.98 0.97 1.00
38 -2.70 0.96 0.97 0.97 0.96 1.00
39 -2.40 0.98 0.97 0.99 0.97 1.00
40 -2.10 0.98 0.97 0.99 0.96 1.00
41 -1.80 0.98 0.97 0.99 0.96 1.00
42 -1.50 0.98 0.97 0.99 0.97 1.00
43 -1.20 0.97 0.96 0.99 0.97 1.00
44 -0.90 0.98 0.97 0.99 0.96 1.00
45 -0.60 0.98 0.97 0.99 0.97 1.00
46 -0.30 0.97 0.97 0.99 0.96 1.00
47 0.00 0.98 0.97 0.99 0.95 1.00
48 0.30 0.96 0.97 0.99 0.97 1.00
49 0.60 0.98 0.97 0.99 0.97 1.00
50 0.90 0.96 0.97 0.99 0.97 1.00
51 1.20 0.96 0.97 0.96 0.95 1.00
52 1.50 0.95 0.92 0.97 0.92 1.00
53 1.80 0.90 0.95 0.97 0.92 1.00
54 2.10 0.95 0.94 0.99 0.93 1.00
55 2.40 0.97 0.95 0.99 0.93 1.00
56 2.70 0.93 0.96 0.98 0.93 1.00
57 3.00 0.97 0.97 0.98 0.94 1.00
58 3.30 0.96 0.97 0.98 0.94 1.00
59 3.60 0.95 0.97 0.98 0.95 1.00
60 3.90 0.96 0.95 0.99 0.94 1.00
61 4.20 0.95 0.96 0.99 0.94 1.00
62 4.50 0.95 0.97 0.99 0.95 1.00
63 4.80 0.92 0.95 0.99 0.93 1.00
64 5.10 0.93 0.95 0.98 0.95 1.00
65 5.40 0.93 0.95 0.98 0.95 1.00
66 5.70 0.93 0.95 0.98 0.95 1.00
67 6.00 0.93 0.95 0.98 0.95 1.00
68 6.30 0.94 0.96 0.98 0.95 1.00
69 6.60 0.93 0.95 0.98 0.95 1.00
70 6.90 0.93 0.95 0.98 0.94 1.00
71 7.20 0.94 0.96 0.98 0.94 1.00
72 7.50 0.94 0.96 0.98 0.94 1.00
73 7.80 0.93 0.95 0.98 0.94 1.00
74 8.10 0.92 0.95 0.98 0.94 1.00
75 8.40 0.93 0.95 0.98 0.94 1.00
76 8.70 0.93 0.96 0.98 0.94 1.00
77 9.00 0.93 0.95 0.98 0.95 1.00
78 9.30 0.94 0.95 0.99 0.96 1.00
79 9.60 0.94 0.96 0.99 0.96 1.00
80 9.90 0.94 0.96 0.99 0.96 1.00
81 10.20 0.93 0.96 0.99 0.96 1.00
82 10.50 0.93 0.96 0.99 0.95 1.00
83 10.80 0.94 0.97 0.99 0.94 1.00
84 11.10 0.95 0.97 0.99 0.92 1.00
85 11.40 0.93 0.84 0.99 0.60 1.00
86 11.70 0.76 0.92 0.97 0.73 1.00
87 12.00 0.70 0.84 0.91 0.69 1.00
88 12.30 0.69 0.84 0.79 0.68 1.00
89 12.60 0.67 0.83 0.62 0.62 1.00
90 12.90 0.75 0.65 0.56 0.46 1.00
91 2
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Chapter 5: Results of The Head and Neck Pre-Trial Benchmark Case 
Resubmission Analysis. 
 
For both the ART-DECO and COSTAR head and neck trials, if the respective RTQA 
team conducting the benchmark case review judged the submitted contours to be 
non-compliant with the trial protocol then constructive feedback was generated in 
the form of an analysis report and sent to the submitting clinician. The clinician was 
requested to re-submit their updated contours using the feedback contained within 
the analysis report. 
I collected all the pre-trial benchmark case resubmissions for both the ART-DECO 
and COSTAR trials up until June 2012 in DICOM format. Again, the structures 
analysed were grouped together using the same distinct groupings as in chapter 3 – 
target structures (which included the high dose CTV); serial organs at risk (spinal 
cord and brainstem) and parallel organs at risk (parotid gland). Details of these 
grouping are again summarised in Table 7 below. 
 
Group Name 
Structures 
Included in 
Group 
Number of 
Structures 
Analysed 
Total 
Target 
Structures 
(TARGET) 
CTV1 
(high dose 
CTV) 
63 63 
Serial Organs 
(OAR-S) 
Spinal Cord 63 
126 
Brainstem 63 
Parallel 
Organs 
(OAR-P) 
Left Parotid 63 
99 
Right Parotid 36 
 
Table 7: Summary of COSTAR and ARTDECO Target and OAR Contour Groupings 
 
All resubmission contours were analysed for DICE, JACCARD, RIET and 1-GMI indices 
and then compared against their initial submission using the Wilcoxon signed rank 
test to determine whether any statistically significant difference existed. Descriptive 
statistics are summarised for the DICE, JACCARD, RIET and 1-GMI indices for each 
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respective group for both first and final submissions in Table 8. The table also 
includes the mean percentage difference for paired submissions for all the indices 
analysed following contour resubmissions. This was determined by first calculating 
the percentage difference between an individual clinicians first submission contour 
CI value and their final submission contour CI value. The mean was then calculated 
for the whole group and this process was repeated for every structure and CI 
analysed. The results are displayed in the final column of Table 8 and demonstrate 
that there was a positive mean improvement in all four measured conformality 
indices. There was variation though between the three groups in the magnitude of 
the improvement seen. Overall the serial organs seemed to have the highest mean 
percentage difference improvement. It should be noted though that the confidence 
intervals for the serial organ Dice, Van’t Riet and 1-GMI indices did include negative 
percentage values. This would suggest that for some of the re-submitted contours 
analysed following RTQA feedback, the submitting clinician had incorrectly re-
edited their contours prior to resubmitting them. 
The boxplots shown in Figure 20 to Figure 23 illustrate the distribution of the four 
conformity indices between the first and final submission for the Target, OAR-S and 
OAR-P groups. Analysis of the head and neck pre-trial benchmark case resubmission 
data revealed a statistically significant improvement in all measured conformity 
indices (DICE, JACCARD RIET and GMI) for all three groups (TARGET, OAR-S and 
OAR-P) following RTQA feedback. 
As explained in Appendix 1, modification of the layout of the L-CI grid (substituting 
each PI column with re-submissions by the same PI), made it possible to visually 
demonstrate the changes made to a structure over the course of re-submissions. 
Hence, Figure 24 clearly demonstrates how the CTV1, left parotid, right parotid, 
brainstem and spinal cord volumes for a single clinician were improved following 
RTQA feedback over the course of 3 submissions during the ART-DECO pre-trial 
benchmark case period. 
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The L-CI data map helps to identify precisely where adaptations were needed 
following the initial submission and subsequently made following the 2 – 3 
subsequent re-submissions following RTTQA review and feedback. 
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Conformity 
Index 
Types 
of 
Contour 
First 
Submission 
Mean Index 
Value (95%CI) 
Final 
Submission 
Mean Index 
Value 
(95%CI) 
P 
Value 
Mean 
Percentage 
Difference for 
Paired 
Submissions 
(95%CI) 
DICE 
Target 0.80 
(0.78-0.82) 
0.83 
(0.82-0.85) 
P<0.05 
5.8% 
(1.7%-9.8%) 
OAR-S 0.73 
(0.71-0.76) 
0.77 
(0.75-0.78) 
P<0.05 
11.3% 
(-1.2%-23.8%) 
OAR-P 0.74 
(0.72-0.76) 
0.77 
(0.75-0.78) 
P<0.05 
4.4% 
(2.7%-7.2%) 
JACCARD 
Target 0.67 
(0.64-0.69) 
0.74 
(0.72-0.76) 
P<0.05 
12.9% 
(5.8%-20.0%) 
OAR-S 0.59 
(0.57-0.62) 
0.66 
(0.64-0.68) 
P<0.05 
27.0% 
(5.7%-48.4%) 
OAR-P 0.59 
(0.57-0.61) 
0.64 
(0.62-0.66) 
P<0.05 
9.7% 
(6.0%-13.4%) 
RIET 
Target 0.65 
(0.62-0.67) 
0.71 
(0.69-0.73) 
P<0.05 
13.9% 
(4.7%-23.1%) 
OAR-S 0.57 
(0.54-0.59) 
0.61 
(0.59-0.63) 
P<0.05 
38.6% 
(-12.1%-89.3%) 
OAR-P 0.56 
(0.54-0.59) 
0.60 
(0.58-0.62) 
P<0.05 
7.9% 
(4.85-11.0%) 
1-GMI 
Target 0.78 
(0.74-0.81) 
0.82 
(0.80-0.85) 
P<0.05 
10.0% 
(0.3%-19.8%) 
OAR-S 0.77 
(0.74-0.80) 
0.82 
(0.79-0.84) 
P<0.05 
20.8% 
(-3.6%-45.1%) 
OAR-P 0.71 
(0.69-0.74) 
0.75 
(0.73-0.77) 
P<0.05 
6.8% 
(3.6%-9.9%) 
Table 8: Descriptive statistics for DICE, JACCARD. RIET and 1-GMI indice analysis of 1st and final submissions 
for Target, OAR-S and OAR-P Contours 
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Figure 20: Analysis of 1st and final submission DICE indice for Target, OAR-S and OAR-P Contours 
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Figure 21: Analysis of 1st and final submission JACCARD indice for Target, OAR-S and OAR-P Contours 
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Figure 22: Analysis of 1st and final submission RIET indice for Target, OAR-S and OAR-P Contours 
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Figure 23: Analysis of 1st and final submission 1-GMI indice for Target, OAR-S and OAR-P Contours 
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Figure 24: Impact of RTQA Feedback on an Individual Clinician Contouring Demonstrated Using L-CI Data During The ART-DECO Trial (No Conformity i.e. contour not present (L-CI = 0.00); 
Poor conformity; Good conformity; Perfect conformity (L-CI = 1.00))
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Chapter 6: Discussion 
 
Head and Neck Pre-Trial Benchmark Cases 
 
Analysis of the ART-DECO and COSTAR pre-trial benchmark case target volumes, 
serial organs (OAR-S) and parallel organs (OAR-P) volumes has revealed that a 
statistically significant difference does exist between clinician target and organ at 
risk volumes. Therefore, the hypothesis that there is a significant level of inter-
observer variation amongst clinical oncologist’s target volume and OAR contours 
within the context of the pre-trial quality assurance (QA) benchmark cases for two 
different UK head and neck radiotherapy trials can be accepted. 
Table 3 summarises the descriptive statistics for all four indices analysed and 
reveals relatively high levels of conformity for both the Dice and 1-GMI conformity 
indices (indice range 0.71 – 0.80) for the target structure and parallel and serial 
organs at risk volumes. The Jaccard Index and Van’t Riet indices for all three groups 
were lower though with values ranging between 0.56 and 0.67. 
The Jaccard Conformity Index is the ratio of intersection of two volumes, as 
compared with the union of the two volumes under comparison. The Dice co-
efficient and Van’t Riet indice are mathematically similar to the Jaccard Index but 
also assess for variations in under and over outlining respectively. 
The results reveal that all three groups had high levels of conformity when analysed 
using the Dice co-efficient (range 0.73 – 0.80). Slightly lower levels of conformity 
were seen when measured using the Jaccard Conformity Index (range 0.59 – 0.67) 
and Van’t Riet indice (range 0.56 – 0.65). My analysis suggests low levels of under-
outlining based upon both the Dice co-efficient and 1-GMI results (the 1-GMI 
results ranged between 0.71 – 0.78). For all four indices, the highest levels of 
conformality were seen in the target group with lower, albeit similar levels of 
conformality, in the serial and parallel organ at risk groups. 
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Comparison of the three groups also revealed that there were statistical differences 
between the target group and the serial and parallel organ at risk groups for the 
Dice, Jaccard and Van’t Riet indices (p<0.05). These results suggest that clinician 
target outlining within the benchmark cases is more consistent than organ at risk 
outlining. This could be explained on the basis that the target volume contains the 
tumour (or an area at risk of harbouring residual tumour cells post-surgery) and is 
therefore deemed by the clinician to be the most important volume to be defined 
because sub-optimal definition negatively impacts on the chances of cure. Hence it 
is therefore likely to be the volume defined most accurately by the treating 
clinician.  
This concept might also explain why the target group had such low levels of under 
outlining when assessed using the Dice co-efficient (mean value 0.80) and 1-GMI 
indices (mean value 0.78). When defining the target volume i.e. the GTV or CTV, 
clinicians will always try to avoid missing out macroscopic tumour or areas 
considered to be at-risk of harbouring microscopic disease from their volume. 
Hence, it would seem more likely that clinicians will tend to over outline rather than 
under outline their target volume. Assessment of the Van’t Riet index for the target 
group was lower than that of the Dice co-efficient (mean value 0.65) and would 
seem to support this. 
It should be noted that target volume definition (CTV1) within both the ART-DECO 
and COSTAR trial outlining protocols was comprehensively covered. Participating 
clinicians were instructed to define their target volumes (CTV1) using normal 
anatomical boundaries and their respective landmarks. This is likely to have 
reduced inter-observer variation as anatomical landmarks tend to be well defined 
and easy to locate in head and neck normal tissue CT and MRI atlases. Both the 
trials’ respective radiotherapy planning packs also contained nodal atlases, 
guidance on which nodal levels to include in the high dose volume (CTV1) and 
comprehensive example cases with example contours defined on example CT data 
sets. This level of information is likely to have reduced inter-observer variability and 
led to the improved conformality detected through my analysis of the target 
contours. 
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Conversely, the radiotherapy planning packs for both the trials contained much less 
information to aid clinician contouring of organs at risk structures. In the case of the 
parotid glands (parallel organ at risk group), brainstem and spinal cord (serial organ 
at risk group), clinicians were instructed to outline them with little or no 
information on their normal anatomical boundaries or an atlas to visually aid their 
definition. Consequently, this might help to explain why the organ at risk values 
were lower than those seen for the target volume group. 
Analysis of the serial and parallel contour groups did not reveal any statistically 
significant differences for the DICE, Jaccard or Van’t Riet indices. This would suggest 
that both groups were contoured equally well by the submitting clinicians although 
as already discussed, not as well as the target group. There was a statistically 
significant difference detected in the 1-GMI results for the serial and parallel organ 
groups. Review of Table 3 also reveals that the parallel organs had higher levels of 
under outlining when compared to the serial organ group. This might be explained 
on the basis that the true extent of the parallel organs (parotid glands) are more 
difficult to accurately define than the serial organs (spinal cord and brainstem) and 
that the radiotherapy planning packs contained relatively less information to aid 
their delineation than compared to the target volume group. 
The UK SCOPE I trial revealed a Jaccard Conformity Index (JCI) for investigator GTV’s 
of 0.69 which they found was comparable with JCI values published in three 
different studies (JCI values 0.69 – 0.72) [57, 61-63]. The mean JCI value for the 
ART-DECO and COSTAR trial target volume group was 0.67 (CI 0.64 – 0.69) which 
would seem consistent with those previously published. Hence, target volume 
conformality within the ART-DECO and COSTAR trials would seem to be consistent 
with that seen in the UK SCOPE I trial and other published studies [57, 61-63]. 
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Lung Pre-Trial Benchmark Cases 
 
Analysis of the IDEAL and i-START pre-trial benchmark case target volumes, serial 
organs (OAR-S) and parallel organs (OAR-P) volumes has revealed that a statistically 
significant difference does exist between clinician target and organ at risk volumes. 
Therefore, the hypothesis that there is a significant level of inter-observer variation 
amongst clinical oncologist’s target volume and OAR contours within the context of 
the pre-trial quality assurance (QA) benchmark cases for two different UK lung 
radiotherapy trials can be accepted. 
Table 5 summarises the descriptive statistics for all four indices analysed and 
reveals high levels of conformity for the Dice, Jaccard, Van’t Riet and 1-GMI 
conformity indices for the target structure and the parallel organ at risk groups 
(indice range 0.72 – 0.95). The serial organ at risk group though had relatively lower 
values for all four measured indices with the lowest being the Van’t Riet (mean 
value 0.50), then the Jaccard Index (mean value 0.54) followed by the Dice co-
efficient (mean value 0.69) and finally the highest being the 1-GMI indice (mean 
value 0.74). 
My results would suggest low levels of both under and over outlining in the target 
and parallel organ at risk groups based upon the results of the DICE co-efficient, 
Van’t Riet and 1-GMI indices. For the target structure group (CTV1), the mean 
indice values for DICE, Van’t Riet and 1-GMI were 0.84 (CI 0.81 – 0.87), 0.72 (CI 0.68 
– 0.77) and 0.86 (CI 0.82 – 0.90) respectively. For the parallel organs at risk group 
(heart and lungs) the mean indice values for DICE, Van’t Riet and 1-GMI were 0.95 
(CI 0.95 – 0.96), 0.91 (CI 0.90 – 0.92) and 0.94 (CI 0.93 – 0.95) respectively. For the 
serial organs at risk group (spinal cord and oesophagus), my results would suggest 
higher levels of under-outlining based on the mean 1-GMI (0.74; CI 0.70 – 0.79) and 
Dice (0.69; CI 0.65 – 0.72) results. Based on the Van’t Riet results seen in the serial 
organs at risk group (mean 0.50; CI 0.47 – 0.54), over outlining also seemed to be 
an issue in this group. 
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A study of Figure 14 which displays the distribution of conformity indices for each 
individual structure analysed reveals some unexpected results. Unlike in the UK 
head and neck radiotherapy trial data where CTV1 (Target Structure Group) had the 
highest overall mean conformity index values, in the UK lung radiotherapy trial 
benchmark case data, CTV1 was ranked 3rd overall in the group with the remaining 
structures ordered as shown in Table 6. 
This ranking would suggest that in the context of the IDEAL and i-START trials, the 
lung volumes had the highest levels of conformity whilst the oesophagus had the 
lowest. Compared with the head and neck rankings (Figure 8), this is very different 
because CTV1 ranked first overall (Target Structures), the spinal cord and brainstem 
(OAR-S) second, and the parotid glands (OAR-P) third. 
In the head and neck trial data discussion it was postulated that the target volumes 
are the ones most likely to have the highest conformity values because they contain 
the tumour target (or an area considered at high risk of containing microscopic 
disease) and therefore are the ones clinicians are likely to outline most accurately. 
It is therefore interesting to see in the lung trial data analysis that the target volume 
comes third, below the parallel organ at risk contours (lung and heart respectively). 
In the head and neck trials, target volumes (CTV1) were defined using 
comprehensive outlining guidelines which referenced anatomical boundaries and 
anatomical landmarks to help guide head and neck clinicians contouring. In the 
IDEAL and i-START trials though, the radiotherapy outlining protocols did not 
contain such detailed guidance because typically in lung cancer, the CTV is normally 
a geometric expansion of the GTV edited off normal structure boundaries. 
Therefore, the CTV1 volume in lung cancer contouring can be at greater risk of 
inter-observer variation as it is ultimately defined by the underlying GTV volume 
which is essentially delineated by the treating lung clinician using all available 
diagnostic imaging and the clinician’s own interpretation of the CT planning scan. 
The process of defining the GTV volume relies heavily on the delineating clinician’s 
own ability to interpret the diagnostic imaging findings and the boundaries of 
normal and abnormal anatomy on the patient’s radiotherapy planning scan. 
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Thus, based on my findings, it would seem there is greater uncertainty and 
therefore more likelihood of inter-observer variation during lung cancer target 
volume delineation. Consequently, this might explain why in the IDEAL and i-START 
structure analysis, the CTV1 structure came 3rd in the rankings of structures based 
on the outcome of the conformality analysis (Table 6). 
What is also interesting from the structure rankings is that the lung contours, which 
are normally auto-contoured using the auto-segmentation function of the 
treatment planning system and therefore not normally outlined by the treating 
clinician, are first in the rankings. These findings would seem to validate the ability 
of the auto-segmentation software to accurately outline lungs based on the high 
levels of conformality seen for the submitted lung contours when compared against 
the TMGs reference contours. 
The other unexpected finding based on Figure 14, is that the heart outline came 
second amongst the structure rankings. This again conflicts with the concept that 
serial organs are easier to outline than parallel ones based on the idea that serial 
organs are tubular in shape, whereas parallel organs typically have more varied 
geometrical borders. What also highlights this unexpected finding further is that the 
lowest ranked structures (4th and 5th) were the spinal cord and oesophagus 
respectively. Both these structures are considered serial organs and anatomically 
are normally long tubular structures. These findings would seem to cast doubt on 
the idea that serial structures are easier to outline than parallel ones based on their 
geometric properties and would suggest that certainly in the case of the 
oesophagus, based on its anatomical location and proximity to other central 
mediastinal structures, it is difficult to interpret its precise boundaries and 
anatomical course. 
Analysis of the three groups revealed that there were statistically significant 
differences between the target group and the serial and parallel OAR groups for all 
four indices analysed (p<0.05). The results of the analysis would seem to validate 
the differences seen in the mean indices for Dice, Jaccard Index, Van’t Riet and 1-
GMI for target and organ at risk contours detailed in the discussion above. 
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The mean JCI value for the IDEAL and i-START trial target volume group was 0.73 (CI 
0.69 – 0.77) and seems consistent with the published UK SCOPE I trial target volume 
JCI of 0.69. Hence, target volume conformality within the IDEAL and i-START trials 
seems to be consistent with that seen in the UK SCOPE I trial. 
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Impact of RTQA Feedback on Head and Neck Pre-Trial Benchmark Case 
Resubmissions 
 
Analysis of the head and neck pre-trial benchmark case resubmission data found 
statistically significant differences between the first and the final target, OAR-P and 
OAR-S contours submitted for RTQA assessment (p<0.05). In fact, the target, OAR-P 
and OAR-S structures analysed from the ART-DECO and COSTAR benchmark cases 
showed statistically significant improvements in all 4 conformity indices analysed 
(p<0.05). Based on this, the hypothesis that RTQA feedback during the pre-trial 
benchmark period does positively influence head and neck clinician contouring can 
be accepted. 
Analysis of the resubmitted head and neck benchmark cases using L-CI data maps 
has also helped to demonstrate how a clinician’s contours evolve over the course of 
RTQA feedback and subsequent re-submissions. Figure 24 clearly demonstrates 
how one clinician’s contours evolved over the course of a total of 3 submissions. 
For instance, on the first submission, Figure 24 reveals that the clinician’s CTV1 and 
brainstem contours had low levels of conformity on CT slices 87 – 100 and 53 – 66 
respectively. Following RTQA feedback and subsequent resubmission, column 2 
now reveals improved conformality for both structures compared with the TMG 
reference contours (shown in column 4). Using the L-CI data map shown in Figure 
24, it would seem the submitting clinician re-contoured CT slices 91 – 104 and 55 – 
74 of their CTV1 and brainstem respectively. They also removed two erroneous 
slices of their brainstem contour (CT slices 79 and 80) and inspection of their spinal 
cord contour reveals these were added correctly to this structure instead to 
improve the junction point between the brainstem and spinal cord structures. 
Inspection of the third submission L-CI data map (column 3) suggests no further 
amendments were made to their CTV1 contour but they did add new contours on 
CT slices 53 – 54 for their brainstem (although the conformality of these contours 
was lower compared with others contained within the structure (LCI values 0.42 
and 0.46 respectively)). 
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Overall, Figure 24 demonstrates the value of the L-CI data maps in helping to 
highlight areas of high and low contouring conformity over the full extent of a 
clinicians delineated target volume or OAR structure. The L-CI data map allows 
immediate recognition of where issues may lie and helps to direct attention to 
where greater scrutiny is needed to try to explain why conformality is lower than 
expected e.g. misinterpretation of normal anatomy or misunderstanding of the 
radiotherapy protocol. 
The L-CI is also capable of revealing precisely how RTQA feedback, following RTQA 
review, can influence clinician contouring on a CT slice by slice basis following 
subsequent resubmissions. Through this enhanced level of detail, the L-CI helps to 
explain why there was a statistically significant improvement in all 4 conformity 
indices analysed for the head and neck structures which underwent RTQA review 
and subsequent feedback during the ART-DECO and COSTAR pre-trial benchmark 
period. The L-CI is therefore a valuable tool which complements other conformity 
indices (i.e. Dice, Jaccard, Van’t Riet and GMI) because unlike those other indices, 
which are effectively 1-dimensional due to their single integer assessment of 
clinician conformality, the L-CI can display a 2-dimensional map of conformity and 
thus can display a more nuanced level of detail. 
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Chapter 7: Conclusions 
 
Analysis of the pre-trial benchmark cases from UK head and neck and lung cancer 
trials has yielded a wealth of data highlighting the degree of inter-observer 
variability that exists in contouring in UK radiotherapy trials. The results of the 
analysis have revealed that most of the target volumes and OAR contours analysed 
from the pre-trial benchmark cases met published standards (JCI values ≥ 0.69) [83, 
87-89]. It was also revealed that target volumes are not always the ones to have the 
highest levels of contouring conformity. Variation in the levels of target volume and 
OAR contouring conformity was found to exist between the head and neck and lung 
cancer trials and raised important questions why these differences might exist. 
Based on the head and neck pre-trial benchmark cases, it seems that more 
information within the radiotherapy outlining protocol relating to target volume 
contouring combined with an anatomical approach to target volume boundaries 
helps to improve target volume conformality amongst clinicians. Conversely, it 
would also seem that a lack of detail defining the anatomical boundaries of organs 
at risk also results in lower levels of clinician conformity. Thus, it would seem vitally 
important that to ensure adequate conformity amongst clinicians that the 
radiotherapy trial outlining protocol contains detailed information on how target 
volume and organ at risk volumes should be defined with example cases and/or CT 
atlases for clinician use. 
Analysis of the lung cancer pre-trial benchmark cases has also revealed unexpected 
findings regarding the rankings of the target and organ at risk contours based on 
their respective conformity indice values. My results found the target volume to be 
in the middle of the rankings with the parallel organ at risk volumes at the top and 
the serial organ at risk volumes at the bottom. This seems surprising as I would 
have hypothesised that the volume containing the tumour target would have a 
higher level of conformity than the organ at risk volumes on the basis that they are 
the most critical ones for achieving a potential cure. 
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However, based on the results this was not the case and instead the highest ranked 
structure was the lung contours which are typically automatically outlined by the 
treatment planning software rather than a human being. These results though do 
seem to validate the ability of radiotherapy treatment planning software to auto-
contour normal lung volumes with a very high degree of conformality (range 0.91 – 
0.95 for the four indices analysed). Therefore, I suspect that as radiotherapy 
treatment planning software continues to advance that its ability to auto-contour 
other normal organs might also develop with hopefully the same high level of 
conformality it can currently achieve when delineating the normal lungs. 
The analysis of the lung cancer benchmark cases has again also highlighted the 
importance of including detailed and systematic instructions on the outlining of 
target and normal structures. Given the relatively low conformality indice values for 
the spinal cord and oesophagus contours it seems imperative that future 
radiotherapy trial outlining protocols include clear definitions and systematic 
instructions on how to outline normal organs at risk. The inclusion of an atlas 
should also be considered so to demonstrate more clearly how the normal organ 
should be defined on a CT slice by slice basis. These measures lead to improved 
conformality amongst participating clinicians as demonstrated by the results of the 
head and neck pre-trial benchmark case analysis where the radiotherapy outlining 
protocol did include some of these measures. 
This research has also demonstrated the value of the local conformity index (L-CI) in 
helping to pinpoint quickly and easily the precise area(s) within contoured 
structures where the highest levels of inter-observer variability exist (Figure 9 – 
Figure 12, Figure 15 – Figure 19 and Figure 24 help demonstrate this). As opposed 
to the Dice, Jaccard, Van’t Riet and GMI indices, the L-CI allows the reviewer’s 
attention to be quickly directed to those underperforming areas within the 
delineated structure to help try and explain why conformality is lower than 
expected e.g. misinterpretation of normal anatomy or misunderstanding of the 
radiotherapy protocol. The Dice, Jaccard, Van’t Riet and GMI indices on the other 
hand essentially provide a summary of the structures conformity with the added 
benefit of information on under or over outlining depending on the indice used. The 
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L-CI however offers itself as a broader tool than those more traditional conformity 
indices as it can be used during the RTQA review process to provide more detailed 
feedback on structure outlining e.g. feedback on a CT slice by slice basis. 
However, the process of creating the L-CI is more intensive and time consuming 
than compared with analysing the traditional Dice, Jaccard, Van’t Riet and GMI 
indices and should therefore only really be considered when such a level of detail is 
truly needed e.g. adding a deeper layer of information to help explain why a 
measured traditional indice might be lower than one might expect. Thus, the L-CI 
complements the traditional indices which are themselves able to provide a more 
rapid, one dimensional assessment of contouring conformity.  
By combining the pre-trial benchmark cases with the L-CI it also allows the 
radiotherapy trial management group to dynamically monitor, and if necessary, 
review and update the radiotherapy outlining protocol to overcome potential 
shortcomings. For instance, if analysis of the pre-trial benchmark cases using the L-
CI were to reveal unexpectedly low levels of conformality for an organ at risk or 
target structure then it could help prompt a review of the radiotherapy outlining 
protocol to determine whether more can be done to reduce inter-observer 
variability. This could involve improved guidance on how the structure should be 
delineated, the inclusion of an example case or a CT atlas demonstrating how the 
structure is outlined or perhaps a TMG organised contouring workshop for 
participating clinicians.  
Analysis of the resubmitted ART-DECO and COSTAR pre-trial benchmark cases has 
also revealed that radiotherapy quality assurance feedback during the pre-accrual 
benchmark period can improve clinician conformity. This was demonstrated by a 
statistically significant improvement in the mean Dice, Jaccard, Riet and 1-GMI 
indices for all target and OAR structures analysed following resubmission. 
The L-CI data maps were also shown to be invaluable during to RTQA feedback 
process in helping to demonstrate visually on a CT slice by slice basis how individual 
clinician contours evolve over the course of RTQA feedback and subsequent 
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resubmissions. This important finding validates the benefits of radiotherapy quality 
assurance, particularly during the pre-accrual benchmark period.  
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Chapter 8: Future Work 
 
This work has analysed the degree of interobserver variation in the context of UK 
head and neck and lung cancer trials. Work has also already been published on the 
analysis of the UK SCOPE 1 pre-trial benchmark cases which studied inter-observer 
variation in the delineation of oesophageal cancer target volumes [64]. As pre-trial 
benchmark cases are becoming more integrated into UK radiotherapy trials future 
work could include the analysis of said cases in the context of other tumour sites 
such as cervical, bladder, lymphoma and the recent stereotactic radiotherapy 
studies which cover multiple sites within the body. Analysis of these other tumour 
sites could help to determine where the greatest levels of inter-observer variation 
exits in the context of target and organ at risk outlining and help evolve existing and 
future radiotherapy outlining protocols to help reduce inter-observer variability and 
improve target and organ at risk contouring amongst participating clinicians. 
Both the IDEAL and i-START lung cancer radiotherapy trials shared the same pre-
trial benchmark cases, but both had different TMG reference contours for their 
target and organ at risk contours. In future it would be useful to conduct a 
comparative analysis of these two TMG reference contours sets to determine the 
degree of inter-observer variation that can exist between two ‘expert groups’. This 
analysis could lead to some interesting results and subsequent discussion on the 
role of alternative methods for the creation of reference contour sets which can 
influence the degree of inter-observer variability detected during contour 
conformity analysis. 
The Radiation Therapy Oncology Group (RTOG) has utilised the ‘simultaneous truth 
and performance level estimation’ (STAPLE) algorithm to create single reference 
contour sets for its atlases. This technique utilises the STAPLE algorithm to create a 
single contour set from multiple different expert contours [66-69]. Recently this 
method was used to create the reference contour set for the UK’s INTERLACE trial 
which is evaluating the potential benefits of chemotherapy prior to chemoradiation 
for cervical cancer. This method of combining expert opinions to create a reference 
contour set has already been shown by the SCOPE1 team to statistically improve 
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the number of submitting trial clinicians judged as achieving an excellent 
conformity level by 53% [70]. This approach should therefore be seriously 
considered by future TMG groups when defining their reference contours. 
One key element this work has not evaluated is the impact of delineation variability 
on plan dosimetry. Despite seeing inter-observer variation within the context of the 
pre-trial benchmark cases the question remains as to whether this has any direct 
impact on the dose delivered to the target or OAR volumes. Two UK studies have 
assessed this; one utilising the IDEAL trial patient data set and the other the Isotoxic 
Lung pre-trial benchmark cases. Both studies investigated the impact inter-observer 
variation in OAR contouring had on radiotherapy plan dosimetry [71, 72]. 
The IDEAL trial dosimetry audit utilised sixty-six patient contour sets. Each patient’s 
contours were assessed by the trial chief investigator and the trial RTTQA 
dosimetrist. Adjustments were made to the contours if there was agreement by the 
two assessors. Dose volume histograms (DVHs) were calculated for both the 
original and the edited volumes and then used to determine whether there was any 
difference in the isotoxic dose prescription. The results showed no changes to the 
prescription dose when editing the heart, brachial plexus or spinal cord PRV 
volumes. Seven out of sixty-six patients (10.6%) had differences in the final 
prescribed dose calculated due to changes in the oesophagus (4/66) and Lungs-GTV 
(3/66) outlining. They found that the mean difference in final prescribed dose was 
0.6Gy (range: 0.2 – 1.1Gy) for oesophagus and 3.2Gy (2.5 – 4.5Gy) for lungs-GTV 
[71].  
In the second study five prospective principal investigators for the Isotoxic Lung 
IMRT trial were recruited and each provided with an atlas of OAR contours. Each 
investigator, using the atlas, was asked to submit outlining cases which were then 
assessed for protocol compliance using the TMG consensus OAR contours. A total 
of twenty-five individual OAR contours were analysed including the spinal canal, 
brachial plexus, oesophagus, heart and mediastinal envelope. Comparing against 
the DVHs of the TMG consensus OARs the median difference in dose received by 
1cc of the brachial plexus was 16.47% (IQR 50.40%), by 1cc of oesophagus 12.68% 
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(IQR 1.13%), by 1cc of heart 0.03% (IQR 0.06%) and by 1cc of mediastinal envelope 
0.24% (IQR 0.02%). The difference in mean heart dose was 1.99% (IQR 1.01%). 
Overall, they found no difference in the final isotoxic prescription dose for any of 
the cases analysed [72]. 
These small studies suggest that inter-observer variation in OAR delineation can 
have an impact on both the final prescription dose and the dose received by the 
contoured OAR. This could have clinical implications if the difference was significant 
but was shown to be small in both these studies. Whether the same can be said for 
the head and neck and lung trial benchmark cases analysed here is not known but 
could form the basis of a future extension of this work. 
Also leading on from this question is the potential impact inter-observer variation in 
OAR and target outlining can have both treatment toxicity and clinical outcomes. A 
future extension of this work might be to establish whether any correlation exists 
between high level of inter-observer variation during the pre-trial benchmark 
period and subsequent toxicity rates and clinical outcomes, including rates of local 
relapse, following completion and publication of the final trial results. 
Finally, one question this research has not answered is whether the improvement 
radiotherapy quality assurance can have on clinician conformality during the pre-
accrual benchmark period is maintained during the entire course of the 
radiotherapy trial. This would be an interesting question to study in a future 
extension of this work and might be answered by mandating that all participating 
clinicians must repeat a benchmark case exercise at pre-defined time points over 
the course of the trial recruitment period e.g. every 12 months. Analysis of these 
subsequent benchmark cases might establish whether inter-observer variation in 
target and OAR contouring deteriorates beyond the completion of the initial pre-
trial benchmark period. 
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Appendix 1 
 
Using Microsoft Excel 2016, I first created a grid where the first column represented 
the CT slice number and the second it’s corresponding Z co-ordinate from the 
DICOM CT planning scan. Each row along the Z axis then effectively represented an 
individual CT slice from the DICOM CT dataset i.e. 
 
 
 
The columns along the X axis represented the submitting PI’s; each column 
representing a different clinician i.e. 
 
 
 
1 -58.9
2 -58.7
3 -58.5
4 -58.3
5 -58.1
6 -57.9
7 -57.7
8 -57.5
9 -57.3
… …
196 -19.9
197 -19.7
198 -19.5
199 -19.3
200 -19.1
CT Slice No.
CT Slice Z 
Number
1 2 3 4 5 … 16 17 18
PI No.
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Finally, the last column on the X axis always represented the tumour management 
group (TMG) reference contour (termed the ‘gold standard’) for the structure being 
analysed i.e. 
 
These elements were then combined to create a grid where each column on the X 
axis represented either a submitting clinician or the ‘gold standard’ and each row 
on the Z axis represented an individual CT slices from the pre-trial benchmark case 
CT dataset:  
 
 
Gold Standard
44 -50.3
45 -50.1
46 -49.9
47 -49.7
48 -49.5
49 -49.3
50 -49.1
51 -48.9
52 -48.7
53 -48.5
54 -48.3
55 -48.1
56 -47.9
57 -47.7
58 -47.5
59 -47.3
60 -47.1
61 -46.9
62 -46.7
63 -46.5
64 -46.3
65 -46.1
66 -45.9
67 -45.7
68 -45.5
69 -45.3
70 -45.1
71 -44.9
72 -44.7
73 -44.5
74 -44.3
75 -44.1
76 -43.9
77 -43.7
78 -43.5
79 -43.3
80 -43.1
81 -42.9
82 -42.7
83 -42.5
84 -42.3
85 -42.1
86 -41.9
87 -41.7
88 -41.5
89 -41.3
90 -41.1
91 -40.9
92 -40.7
93 -40.5
CT Slice No. Z
PI No.
Gold 
Standard1 2 3 4 10 11 12 13 145 6 7 8 9 15 16 17 18
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The example grid above comes from the first ART DECO pre-trial benchmark case. 
As can be seen, there were a total of 18 submitting clinicians plus the ‘gold 
standard’ (represented by individual columns along the X axis). The original 
planning CT dataset comprised a total of 200 individual CT slices but for this 
example, the grid above only demonstrates CT slice number 44 (Z = -50.3) to CT 
slice number 93 (Z = -40.5) (along the Z axis). 
Using this grid, it was now possible to paste the L-CI data output from MATLAB into 
the Excel 2016 spreadsheet. MATLAB had created an individual L-CI file for each 
different structure analysed and this file contained L-CI data for each submitting 
clinician. The example below demonstrates the use of the grid to represent the 
brainstem L-CI data calculated using MATLAB for the first ART DECO pre-trial 
benchmark case: 
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Finally, to increase the ease of visual interpretation of the data, the L-CI data was 
‘colour coded’ using the conditional formatting tool within Microsoft Excel 2016. 
Conditional formatting in Excel enables you to highlight cells with a certain colour, 
depending on the cell's value. For the purposes of the L-CI data this colour 
highlighting was defined as: 
• No Conformity i.e. contour not present (L-CI = 0.00) 
• Poor conformity 
• Good conformity 
• Perfect conformity (L-CI = 1.00)  
44 -50.3
45 -50.1
46 -49.9
47 -49.7 0.00
48 -49.5 0.00
49 -49.3 0.00 0.00
50 -49.1 0.00 0.00 0.00
51 -48.9 0.00 0.00 0.00 0.00
52 -48.7 0.00 0.00 0.00 0.00 0.00
53 -48.5 0.00 0.00 0.00 0.00 0.00 0.83 0.00 0.00 0.34 0.90 0.84 0.00 0.00 0.74 0.84 0.00 0.70 0.00 1.00
54 -48.3 0.00 0.00 0.00 0.00 0.83 0.87 0.00 0.00 0.82 0.90 0.78 0.00 0.00 0.72 0.86 0.78 0.68 0.00 1.00
55 -48.1 0.50 0.43 0.32 0.00 0.79 0.83 0.00 0.37 0.76 0.90 0.79 0.00 0.00 0.70 0.86 0.72 0.67 0.00 1.00
56 -47.9 0.62 0.40 0.64 0.76 0.78 0.87 0.00 0.54 0.70 0.81 0.69 0.00 0.00 0.76 0.85 0.77 0.67 0.80 1.00
57 -47.7 0.91 0.41 0.88 0.87 0.82 0.88 0.00 0.56 0.83 0.87 0.71 0.84 0.84 0.83 0.88 0.86 0.76 0.90 1.00
58 -47.5 0.89 0.41 0.81 0.87 0.83 0.85 0.00 0.55 0.86 0.85 0.76 0.82 0.82 0.77 0.87 0.83 0.72 0.90 1.00
59 -47.3 0.79 0.36 0.85 0.77 0.77 0.78 0.00 0.56 0.71 0.77 0.67 0.76 0.76 0.68 0.79 0.83 0.66 0.79 1.00
60 -47.1 0.89 0.42 0.85 0.75 0.91 0.79 0.00 0.64 0.86 0.89 0.67 0.88 0.88 0.67 0.84 0.88 0.81 0.84 1.00
61 -46.9 0.78 0.51 0.71 0.75 0.85 0.57 0.00 0.81 0.84 0.78 0.52 0.77 0.77 0.64 0.84 0.81 0.86 0.76 1.00
62 -46.7 0.77 0.53 0.66 0.69 0.87 0.57 0.00 0.71 0.85 0.71 0.69 0.76 0.76 0.53 0.77 0.82 0.86 0.75 1.00
63 -46.5 0.74 0.53 0.79 0.63 0.81 0.51 0.00 0.64 0.90 0.68 0.58 0.75 0.75 0.57 0.70 0.84 0.84 0.73 1.00
64 -46.3 0.79 0.55 0.82 0.55 0.76 0.56 0.00 0.70 0.89 0.73 0.56 0.74 0.74 0.57 0.65 0.80 0.81 0.77 1.00
65 -46.1 0.83 0.56 0.85 0.55 0.68 0.67 0.00 0.69 0.83 0.85 0.65 0.73 0.73 0.56 0.67 0.75 0.77 0.79 1.00
66 -45.9 0.90 0.53 0.75 0.51 0.59 0.68 0.00 0.63 0.76 0.78 0.55 0.75 0.75 0.55 0.75 0.81 0.73 0.74 1.00
67 -45.7 0.89 0.50 0.81 0.49 0.53 0.73 0.55 0.66 0.73 0.54 0.58 0.70 0.70 0.54 0.72 0.81 0.68 0.68 1.00
68 -45.5 0.71 0.47 0.81 0.41 0.51 0.70 0.51 0.60 0.57 0.45 0.35 0.51 0.51 0.55 0.63 0.75 0.64 0.59 1.00
69 -45.3 0.56 0.45 0.70 0.44 0.50 0.69 0.52 0.63 0.61 0.43 0.39 0.42 0.42 0.51 0.57 0.73 0.64 0.50 1.00
70 -45.1 0.59 0.43 0.74 0.40 0.50 0.72 0.52 0.53 0.47 0.43 0.32 0.42 0.42 0.47 0.57 0.75 0.63 0.48 1.00
71 -44.9 0.60 0.44 0.75 0.41 0.49 0.69 0.51 0.62 0.41 0.45 0.36 0.45 0.45 0.42 0.56 0.83 0.61 0.39 1.00
72 -44.7 0.62 0.44 0.83 0.46 0.50 0.80 0.56 0.65 0.52 0.48 0.45 0.54 0.54 0.47 0.56 0.80 0.61 0.36 1.00
73 -44.5 0.63 0.43 0.83 0.50 0.48 0.81 0.54 0.58 0.53 0.51 0.55 0.55 0.55 0.48 0.61 0.80 0.59 0.31 1.00
74 -44.3 0.67 0.51 0.72 0.57 0.55 0.75 0.49 0.69 0.68 0.61 0.53 0.67 0.67 0.53 0.75 0.71 0.63 0.31 1.00
75 -44.1 0.69 0.58 0.52 0.55 0.55 0.74 0.42 0.48 0.59 0.67 0.52 0.71 0.71 0.56 0.66 0.58 0.63 0.35 1.00
76 -43.9 0.67 0.71 0.00 0.57 0.61 0.60 0.35 0.47 0.66 0.71 0.51 0.77 0.77 0.58 0.59 0.00 0.64 0.41 1.00
77 -43.7 0.59 0.84 0.00 0.74 0.63 0.60 0.29 0.58 0.69 0.74 0.47 0.73 0.73 0.64 0.70 0.00 0.63 0.46 1.00
78 -43.5 0.66 0.86 0.00 0.00 0.00 0.61 0.24 0.60 0.73 0.77 0.28 0.72 0.72 0.60 0.70 0.00 0.63 0.50 1.00
79 -43.3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
80 -43.1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
81 -42.9 0.00 0.00 0.00 0.00
82 -42.7 0.00 0.00
83 -42.5 0.00 0.00
84 -42.3 0.00
85 -42.1 0.00
86 -41.9 0.00
87 -41.7 0.00
88 -41.5 0.00
89 -41.3 0.00
90 -41.1 0.00
91 -40.9
92 -40.7
93 -40.5
CT Slice No. Z
PI No.
Gold 
Standard1 2 3 4 10 11 12 13 145 6 7 8 9 15 16 17 18
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Again, using the brainstem L-CI data from the first ART DECO pre-trial benchmark 
case as an example, applying conditional formatting using the above rules, the data 
becomes visually easier to interpret: 
 
 
Key: No Conformity i.e. contour not present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity 
(L-CI = 1.00) 
 
44 -50.3
45 -50.1
46 -49.9
47 -49.7 0.00
48 -49.5 0.00
49 -49.3 0.00 0.00
50 -49.1 0.00 0.00 0.00
51 -48.9 0.00 0.00 0.00 0.00
52 -48.7 0.00 0.00 0.00 0.00 0.00
53 -48.5 0.00 0.00 0.00 0.00 0.00 0.83 0.00 0.00 0.34 0.90 0.84 0.00 0.00 0.74 0.84 0.00 0.70 0.00 1.00
54 -48.3 0.00 0.00 0.00 0.00 0.83 0.87 0.00 0.00 0.82 0.90 0.78 0.00 0.00 0.72 0.86 0.78 0.68 0.00 1.00
55 -48.1 0.50 0.43 0.32 0.00 0.79 0.83 0.00 0.37 0.76 0.90 0.79 0.00 0.00 0.70 0.86 0.72 0.67 0.00 1.00
56 -47.9 0.62 0.40 0.64 0.76 0.78 0.87 0.00 0.54 0.70 0.81 0.69 0.00 0.00 0.76 0.85 0.77 0.67 0.80 1.00
57 -47.7 0.91 0.41 0.88 0.87 0.82 0.88 0.00 0.56 0.83 0.87 0.71 0.84 0.84 0.83 0.88 0.86 0.76 0.90 1.00
58 -47.5 0.89 0.41 0.81 0.87 0.83 0.85 0.00 0.55 0.86 0.85 0.76 0.82 0.82 0.77 0.87 0.83 0.72 0.90 1.00
59 -47.3 0.79 0.36 0.85 0.77 0.77 0.78 0.00 0.56 0.71 0.77 0.67 0.76 0.76 0.68 0.79 0.83 0.66 0.79 1.00
60 -47.1 0.89 0.42 0.85 0.75 0.91 0.79 0.00 0.64 0.86 0.89 0.67 0.88 0.88 0.67 0.84 0.88 0.81 0.84 1.00
61 -46.9 0.78 0.51 0.71 0.75 0.85 0.57 0.00 0.81 0.84 0.78 0.52 0.77 0.77 0.64 0.84 0.81 0.86 0.76 1.00
62 -46.7 0.77 0.53 0.66 0.69 0.87 0.57 0.00 0.71 0.85 0.71 0.69 0.76 0.76 0.53 0.77 0.82 0.86 0.75 1.00
63 -46.5 0.74 0.53 0.79 0.63 0.81 0.51 0.00 0.64 0.90 0.68 0.58 0.75 0.75 0.57 0.70 0.84 0.84 0.73 1.00
64 -46.3 0.79 0.55 0.82 0.55 0.76 0.56 0.00 0.70 0.89 0.73 0.56 0.74 0.74 0.57 0.65 0.80 0.81 0.77 1.00
65 -46.1 0.83 0.56 0.85 0.55 0.68 0.67 0.00 0.69 0.83 0.85 0.65 0.73 0.73 0.56 0.67 0.75 0.77 0.79 1.00
66 -45.9 0.90 0.53 0.75 0.51 0.59 0.68 0.00 0.63 0.76 0.78 0.55 0.75 0.75 0.55 0.75 0.81 0.73 0.74 1.00
67 -45.7 0.89 0.50 0.81 0.49 0.53 0.73 0.55 0.66 0.73 0.54 0.58 0.70 0.70 0.54 0.72 0.81 0.68 0.68 1.00
68 -45.5 0.71 0.47 0.81 0.41 0.51 0.70 0.51 0.60 0.57 0.45 0.35 0.51 0.51 0.55 0.63 0.75 0.64 0.59 1.00
69 -45.3 0.56 0.45 0.70 0.44 0.50 0.69 0.52 0.63 0.61 0.43 0.39 0.42 0.42 0.51 0.57 0.73 0.64 0.50 1.00
70 -45.1 0.59 0.43 0.74 0.40 0.50 0.72 0.52 0.53 0.47 0.43 0.32 0.42 0.42 0.47 0.57 0.75 0.63 0.48 1.00
71 -44.9 0.60 0.44 0.75 0.41 0.49 0.69 0.51 0.62 0.41 0.45 0.36 0.45 0.45 0.42 0.56 0.83 0.61 0.39 1.00
72 -44.7 0.62 0.44 0.83 0.46 0.50 0.80 0.56 0.65 0.52 0.48 0.45 0.54 0.54 0.47 0.56 0.80 0.61 0.36 1.00
73 -44.5 0.63 0.43 0.83 0.50 0.48 0.81 0.54 0.58 0.53 0.51 0.55 0.55 0.55 0.48 0.61 0.80 0.59 0.31 1.00
74 -44.3 0.67 0.51 0.72 0.57 0.55 0.75 0.49 0.69 0.68 0.61 0.53 0.67 0.67 0.53 0.75 0.71 0.63 0.31 1.00
75 -44.1 0.69 0.58 0.52 0.55 0.55 0.74 0.42 0.48 0.59 0.67 0.52 0.71 0.71 0.56 0.66 0.58 0.63 0.35 1.00
76 -43.9 0.67 0.71 0.00 0.57 0.61 0.60 0.35 0.47 0.66 0.71 0.51 0.77 0.77 0.58 0.59 0.00 0.64 0.41 1.00
77 -43.7 0.59 0.84 0.00 0.74 0.63 0.60 0.29 0.58 0.69 0.74 0.47 0.73 0.73 0.64 0.70 0.00 0.63 0.46 1.00
78 -43.5 0.66 0.86 0.00 0.00 0.00 0.61 0.24 0.60 0.73 0.77 0.28 0.72 0.72 0.60 0.70 0.00 0.63 0.50 1.00
79 -43.3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
80 -43.1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
81 -42.9 0.00 0.00 0.00 0.00
82 -42.7 0.00 0.00
83 -42.5 0.00 0.00
84 -42.3 0.00
85 -42.1 0.00
86 -41.9 0.00
87 -41.7 0.00
88 -41.5 0.00
89 -41.3 0.00
90 -41.1 0.00
91 -40.9
92 -40.7
93 -40.5
CT Slice No. Z
PI No.
Gold 
Standard1 2 3 4 10 11 12 13 145 6 7 8 9 15 16 17 18
Page | 101  
 
With the application of conditional formatting, it now makes it visually easier to 
appreciate areas of over outlining: 
 
Under outlining: 
 
 
 
Higher levels of L-CI agreement (range 0.63 – 0.88): 
 
 
 
  
0.63 0.67 1.00
0.66 0.75 1.00
0.68 0.72 1.00
0.76 0.71 1.00
0.76 0.80 1.00
0.65 0.67 1.00
0.57 0.67 1.00
0.55 0.66 1.00
0.57 0.66 1.00
0.61 0.78 1.00
0.70 0.76 1.00
0.65 0.64 1.00
0.60 0.67 1.00
0.68 0.75 1.00
0.45 0.77 1.00
0.45 0.69 1.00
0.40 0.66 1.00
0.46 0.74 1.00
0.62 0.86 1.00
0.67 0.83 1.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00
0.00
0.00
0.00
0.00
0.00 0.00 1.00
0.00 0.00 1.00
0.62 0.00 1.00
0.59 0.00 1.00
0.61 0.00 1.00
0.59 0.00 1.00
0.66 0.00 1.00
0.66 0.00 1.00
0.62 0.00 1.00
0.68 0.00 1.00
0.63 0.00 1.00
0.61 0.00 1.00
0.66 0.66 1.00
0.70 0.57 1.00
0.68 0.58 1.00
0.77 0.71 1.00
0.67 0.64 1.00
0.63 0.68 1.00
0.73 0.82 0.63 1.00
0.72 0.84 0.70 1.00
0.70 0.78 0.70 1.00
0.88 0.84 0.78 1.00
0.83 0.78 0.73 1.00
0.80 0.77 0.73 1.00
0.76 0.74 0.71 1.00
0.75 0.76 0.71 1.00
0.78 0.80 0.71 1.00
0.82 0.79 0.69 1.00
Page | 102  
 
Lower levels of L-CI agreement (range 0.41 – 0.59): 
 
 
 
For some of the structures analysed, clinicians had also failed to submit a contour 
all together. In the example below, clinician number 2 has failed to submit a CTV1 
contour for analysis and hence the column is empty. 
 
 
Key: No Conformity i.e. contour not present (L-CI = 0.00); Poor conformity; Good conformity; Perfect conformity 
(L-CI = 1.00) 
By slightly modifying the layout of the grid, substituting each PI column with re-
submissions by the same PI, it was also possible to visually demonstrate the 
changes made to a structure over the course of subsequent re-submissions. 
0.44 0.55 0.41 1.00
0.51 0.72 0.49 1.00
0.48 0.59 0.45 1.00
0.47 0.55 0.44 1.00
0.57 0.61 0.54 1.00
0.50 0.56 0.47 1.00
0.51 0.58 0.56 1.00
0.52 0.55 0.59 1.00
0.49 0.54 0.54 1.00
0.49 0.56 0.54 1.00
0.52 0.49 0.54 1.00
0.51 0.57 0.54 1.00
0.52 0.57 0.52 1.00
45 -0.60 0.00
46 -0.30 0.00
47 0.00 0.00
48 0.30 0.00 0.00 0.00
49 0.60 0.74 0.74 0.57 0.75 0.38 0.23 0.84 0.00 1.00
50 0.90 0.60 0.65 0.60 0.82 0.66 0.29 1.00 0.68 1.00
51 1.20 0.64 0.67 0.68 0.83 0.74 0.51 1.00 0.75 1.00
52 1.50 0.68 0.64 0.71 0.86 0.74 0.69 0.93 0.79 1.00
53 1.80 0.72 0.68 0.75 0.90 0.75 0.73 0.90 0.82 1.00
54 2.10 0.73 0.69 0.78 0.91 0.76 0.78 0.87 0.81 1.00
55 2.40 0.74 0.66 0.74 0.90 0.71 0.81 0.84 0.85 1.00
56 2.70 0.76 0.74 0.65 0.87 0.60 0.82 0.70 0.82 1.00
57 3.00 0.80 0.71 0.68 0.87 0.60 0.80 0.71 0.78 1.00
58 3.30 0.82 0.67 0.72 0.85 0.54 0.81 0.76 0.80 1.00
59 3.60 0.81 0.66 0.75 0.84 0.57 0.84 0.82 0.85 1.00
60 3.90 0.82 0.74 0.80 0.82 0.59 0.84 0.85 0.89 1.00
61 4.20 0.85 0.84 0.85 0.81 0.60 0.79 0.89 0.88 1.00
62 4.50 0.87 0.89 0.85 0.83 0.74 0.77 1.00 0.88 1.00
63 4.80 0.84 0.94 0.85 0.91 0.72 0.76 1.00 0.87 1.00
64 5.10 0.78 0.93 0.83 0.91 0.82 0.83 1.00 0.87 1.00
65 5.40 0.76 0.91 0.84 0.91 0.82 0.87 1.00 0.89 1.00
66 5.70 0.79 0.90 0.83 0.88 0.83 0.85 1.00 0.89 1.00
67 6.00 0.88 0.90 0.79 0.78 0.80 0.75 1.00 0.88 1.00
68 6.30 0.87 0.79 0.78 0.86 0.79 0.79 1.00 0.90 1.00
69 6.60 0.88 0.77 0.77 0.87 0.81 0.79 1.00 0.92 1.00
70 6.90 0.82 0.77 0.77 0.84 0.75 0.75 1.00 0.87 1.00
71 7.20 0.81 0.89 0.80 0.63 0.89 0.00 1.00 0.65 1.00
72 7.50 0.66 0.84 0.63 0.62 0.80 0.00 1.00 0.80 1.00
73 7.80 0.00 0.78 0.33 0.00 0.83 0.00 1.00 0.00 1.00
5 6 7 8 9
CT Slice No. Z
PI No.
Gold Standard
1 2 3 4
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The example below demonstrates how the CTV1, left parotid, right parotid, 
brainstem and spinal cord volumes for a single PI evolved over the course of a total 
of 3 submissions during the ART-DECO trial: 
 
 
Figure 25: Example to Show How an Individual PI’s L-CI Data for Several Structures Changes Over the Course 
of Three Submissions (ART-DECO Trial) (No Conformity i.e. contour not present (L-CI = 0.00); Poor conformity; 
Good conformity; Perfect conformity (L-CI = 1.00)) 
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